| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Filing example | BLA | — | Subscribe to access the data. | Cell Therapies | Dermatologic System | ||
BLA Filing example | BLA | — | Subscribe to access the data. | Cell Therapies | Dermatologic System | ||
BLA Filing example | BLA | — | Subscribe to access the data. | Cell Therapies | Dermatologic System |
Recent Updates
Recently added Catalysts
INmune Bio Inc.$1.73
+0.11 (+6.79%)
C 41Pipeline Score Richly Valued Biotech · Clinical
Market Cap
38.55 M
EPS
-1.69
P/E Ratio
-
Value Trade
529.72 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
3.64 M
Operating CF
-3.40 M
Total Assets
25.82 M
Total Liabilities
6.19 M
Equity
19.62 M
D/E Ratio
12,345
-12.65 %
Week
2.84 %
1 Month
9.85 %
3 Month
-3.97 %
6 Month
-88.79 %
5 Year
-82.82 %
All Time
Cash Data
Cash Position
21.36 M
Monthly Burn
1.13 M
Runway
16.1 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
180.53 K
52 Week Range
1.09 - 11.64
% held by Insiders
11.28 %
% held by Institutions
20.96 %
Enterprise Value
18.70 M
Total Shares
26.59 M
Short %
10.1 %
Float Shares
23.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for INmune Bio Inc.
593Total events
13Upcoming
88Tier-1 (high impact)
2017 – 2027Coverage
Upcoming catalysts 2
TBD
T2EU MAA Submission
Subscribe to view catalyst details
TBD
T1BLA Submission
Subscribe to view catalyst details
Event history 2
TBD
▲Manufacturing MilestoneCORDStromFiledCMC / Inspection
Subscribe to view catalyst details
TBD
▲Manufacturing MilestoneEbstrocelFiledCMC / Inspection
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-07-12 | XPro (XPro1595) | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-07-12 | XPro (XPro1595) | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-07-12 | XPro (XPro1595) | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
C41
Pipeline Score $3M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 62%
Micro Cap (rank 348 of 913)
Percentile RankINmune Bio Inc. carries a moderate pipeline score (41/100), with $465M risk-adjusted pipeline value, led by XPro1595 in Alzheimer Disease (Phase 2), across $161B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XPro1595 Small molecule | Alzheimer Disease | Phase 2 | NCT03943264 | 11% | $339M | COMPLETED | 227 | - | - | Sep 1, 2021 | - | Jun 15, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
XPro Fast Track | early Alzheimer's disease | Phase 2 | 2026-07-09 | statistically significant treatment difference at Week 24 (p < 0.01) Read More | INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC Read More | |
XPro Fast Track | early Alzheimer's disease | Phase 2 | 2026-07-09 | statistically significant treatment difference at Week 24 (p < 0.01) Read More | INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC Read More | |
XPro Fast Track | early Alzheimer's disease | Phase 2 | 2026-07-09 | statistically significant treatment difference at Week 24 (p < 0.01) Read More | INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INMB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INMB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INMBINmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
INmune Bio has achieved a significant milestone by completing commercial-ready manufacturing for its CORDStrom™ platform. This advancement supports the planned Phase 3 confirmation trial and regulatory submissions in the US, EU, and UK. The company is now equipped to generate master cell banks for Ebstrocel™, aimed at treating recessive dystrophic epidermolysis bullosa (RDEB). INmune Bio's efforts align with the MHRA's draft regulatory framework for rare disease therapies.
Read more →INMBINmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
INmune Bio's new peer-reviewed study demonstrates that XPro1595 can prevent Alzheimer's pathology and cognitive deficits induced by traumatic brain injury. The research identifies soluble TNF as a critical link between head injuries and Alzheimer's disease, showing that neutralizing this cytokine can mitigate the associated risks. The findings support the potential of XPro1595 in treating Alzheimer's and related conditions.
Read more →INMBINmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
INmune Bio Inc. announced positive Phase 2 imaging data for XPro in early Alzheimer's disease, showing significant treatment-related changes in white matter myelin integrity at Week 24. The data, to be presented at the AAIC, highlights the concordance of white matter and gray matter imaging endpoints, supporting the drug's biologic activity. The findings suggest that XPro may engage relevant biology earlier than traditional volumetric approaches.
Read more →INMBINmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
INmune Bio has advanced its CORDStrom™ platform patent application into the U.S. national phase, following a favorable opinion during the PCT application process. This move solidifies the company's intellectual property strategy and aims to protect its lead product, Ebstrocel, for epidermolysis bullosa. The patent, if granted, could provide exclusive commercial protection until at least 2045.
Read more →INMB▲ +10.4%on this news· ran to +21% by day 3
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
INmune Bio Inc. has received MHRA approval for the Pediatric Investigation Plan (PIP) for Ebstrocel™, aimed at treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). This approval is a crucial step towards the Marketing Authorization Application (MAA) submission in the UK, aligning with the company's timeline for regulatory filings. The swift approval reflects the strength of the clinical data and addresses significant unmet medical needs in a vulnerable patient population.
Read more →INMBINmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
INmune Bio has received positive feedback from the MHRA regarding its planned 2026 Marketing Authorization Application for CORDStrom™ in treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). The agency confirmed alignment on the clinical and manufacturing strategies, acknowledging the Phase 2 data as showing significant symptomatic benefits. However, the study's limitations regarding durable wound closure were noted, prompting refinements in the upcoming Phase 3 trial.
Read more →INMBINmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
INmune Bio reported significant results from its Phase 2 MINDFuL trial of XPro1595 in Alzheimer's patients, showing a strong treatment effect on white matter MRI biomarkers. The findings support the company's precision-medicine approach and align with FDA Fast Track designation for further development. The trial demonstrated enhanced efficacy in patients with elevated inflammatory markers, reinforcing the drug's potential in treating neuroinflammation.
Read more →INMB▼ -7.7%on this news
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
INmune Bio has published results from its Phase 2 MINDFuL trial in Alzheimer's disease, demonstrating the efficacy of XPro™ in patients with inflammation. The study showed positive trends across various cognitive and biomarker endpoints without any observed amyloid-related imaging abnormalities. The findings suggest a promising direction for future clinical trials, particularly in an enriched patient population.
Read more →INMB▲ +15.1%on this newsshared move
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
INmune Bio has received FDA Fast Track designation for XPro1595, a selective soluble TNF inhibitor, aimed at treating early Alzheimer's disease. This designation highlights the urgent need for innovative therapies that address neuroinflammation, a key factor in cognitive decline. The company anticipates closer collaboration with the FDA to expedite the development process.
Read more →INMB▲ +5%on this news· ran to +21% by day 1shared move
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
INmune Bio has been named a founding member of the American Biotech Innovation Alliance (ABIA), a coalition aimed at enhancing U.S. biotechnology leadership. The ABIA will focus on addressing key challenges such as manufacturing capacity and regulatory flexibility. INmune Bio's CEO emphasized the importance of strategic collaboration to maintain the U.S.'s competitive edge in biotech innovation.
Read more →INMBINmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
INmune Bio Inc. has announced its financial results for the first quarter of 2026, showcasing progress in its clinical-stage immunology initiatives. The company is focused on leveraging its proprietary platforms, including CORDStrom™, XPro™, and INKmune™, to develop treatments targeting the innate immune system. A conference call is scheduled to discuss these results and future milestones.
Read more →INMBINmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
INmune Bio and Anthony Nolan have expanded their collaboration to enhance the CORDStrom™ MSC platform, targeting diseases like RDEB and cancer. This partnership will utilize high-quality umbilical cord tissue to create standardized MSC Banks, addressing manufacturing inconsistencies. The agreement includes provisions for quality management and regulatory compliance as they prepare for commercial approval.
Read more →INMB▲ +7.5%on this newsshared move
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
INmune Bio Inc. will host a conference call on May 7, 2026, at 4:30 PM ET to discuss its first quarter financial results and provide a corporate update. The company focuses on treatments for neuroinflammation and Alzheimer's Disease, with several product platforms in development. Participants can join via a dial-in or a live webcast.
Read more →INMBINmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
INmune Bio Inc. has announced promising preclinical data for INB03 (XPro1595), demonstrating its ability to overcome resistance to tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer models. The data, to be presented at AACR 2026, shows that INB03 enhances the efficacy of TKIs while significantly reducing metastatic spread. This positions INB03 as a potential treatment for patients with advanced HER2-positive breast cancer.
Read more →INMBINmune Bio Inc. Announces 2025 Results and Provides Business Update
INmune Bio Inc. has announced its financial results for 2025 and provided updates on its CORDStrom™ and XPro™ programs. The company plans to submit regulatory applications for CORDStrom™ in the UK, EU, and FDA in the near future, while noting successful advancements in its Alzheimer’s treatment program, XPro™. Despite an increase in net loss and some financial impairments, the company has received R&D rebates and maintains a cash runway into 2027. Overall, INmune positions itself for significant advancements in the near term.
Read more →INMBINmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
INmune Bio Inc. will host a conference call on March 30, 2026, to discuss its financial results for the year ended December 31, 2025, and provide a corporate update. The call will include details about their product platforms and ongoing clinical trials. Participants can join via dial-in or a live audio webcast.
Read more →INMBINmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
INmune Bio Inc.'s MINDFuL trial, which focuses on XPro1595 for early Alzheimer's disease, was highlighted at the AD/PD 2026 plenary by Dr. Malú Gámez Tansey. The presentation emphasized the successful alignment of inflammatory biomarker enrichment with the drug's mechanism of action, showcasing a precision medicine strategy. Based on promising Phase 2 results, INmune Bio is set to initiate a Phase 2b/3 trial with a larger cohort of patients. This recognition from a key industry figure underscores the momentum of INmune Bio's approach in the neuroinflammation space.
Read more →INMBModulating the Innate Immune System to Transform Inflammation - Driven Disease 1 Corporate Presentation March 2025 NASDAQ: INMB Disclaimer 2 This presentation has been prepared by INmune Bio. Inc. ("INmune Bio" or the "C
INmune Bio presented a corporate overview outlining its strategy to modulate the innate immune system for treating inflammation-driven diseases. The presentation emphasized the favorable patentability of its drug candidates, including CORDStrom and XPro1595, with potential for extended exclusivity. However, it cautioned that actual results may differ due to inherent risks associated with clinical trials, funding, and regulatory approvals, highlighting the uncertainty surrounding drug development timelines and outcomes.
Read more →INMBINmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
INmune Bio Inc. is hosting a webinar on February 27, 2026, to discuss the registrational strategy for XPro1595, a treatment for early Alzheimer's disease. The session will cover results from the Phase 2 MINDFuL trial and the feedback received from the FDA. Key clinical experts will present findings and discuss the path to Phase 3 studies.
Read more →INMBINmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom for RDEB Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data fro
INmune Bio Inc. has announced an upcoming webinar scheduled for February 26, 2026, focused on new clinical data regarding CORDStrom, a treatment for recessive dystrophic epidermolysis bullosa (RDEB). The session aims to emphasize the systemic, disease-modifying capabilities of CORDStrom, moving beyond current topical care treatments. Clinical investigators from the recent MissionEB Phase III trial will share their insights and experiences with RDEB patients and the novel therapeutic approach of CORDStrom. This highlights the company's commitment to expanding treatment options for complex inflammatory and autoimmune diseases.
Read more →INMB▼ -6.4%on this news
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
INmune Bio announced FDA alignment on its integrated Phase 2b/3 clinical development pathway for XPro1595 in early Alzheimer's disease. The FDA's feedback supports the company's enrichment-led trial design and confirms the CDR-SB as the primary endpoint for Phase 3. This regulatory clarity is seen as a significant milestone for advancing XPro1595 towards registration.
Read more →INMBINmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
INmune Bio has submitted a pre-submission package for CORDStrom to the UK MHRA, marking a significant step toward commercialization for treating recessive dystrophic epidermolysis bullosa (RDEB). The submission aims to streamline the Marketing Authorization Application process. CORDStrom could become the first systemic therapy for RDEB, a rare and debilitating genetic disorder with no current approved systemic treatments.
Read more →INMB▲ +7.8%on this news
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
INmune Bio, Inc. has outlined its achievements in 2025 and strategic plans for 2026 in a shareholder letter. Key highlights include advancements in CORDStrom™ for recessive dystrophic epidermolysis bullosa and promising results from the XPro™ Phase 2 trial for Alzheimer's disease. The company is preparing for regulatory submissions and remains focused on addressing significant unmet medical needs.
Read more →INMB▼ -10.1%on this news
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients Boca Raton, FL
INmune Bio reported new imaging data from its Phase 2 MINDFuL trial of XPro1595, showing promising results in early Alzheimer's patients with high neuroinflammation. The data showcased trends toward slower neurodegeneration and supported the therapy's mechanism of targeting soluble TNF. These findings were presented at the CTAD conference, emphasizing XPro1595's potential as a first-in-class treatment in an underserved patient population. Further analyses are anticipated in 2026 to provide additional insights into the therapy's impact on brain structure.
Read more →INMBINmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference Boca Raton, FL
INmune Bio, Inc. will present two studies at the 18th Clinical Trials on Alzheimer's Disease conference in San Diego from December 1-4, 2025. The first presentation will highlight the Phase 2 MINDFuL trial results for XPro1595, a selective soluble TNF neutralizer targeting inflammation in early Alzheimer's disease. The second study will discuss the validation of the Early Mild Alzheimer's Cognitive Composite through biomarkers. These presentations aim to advance the understanding and treatment options for Alzheimer's disease.
Read more →INMBCorporate Presentation November 2025 NASDAQ: INMB Modulating the Innate Immune System to Transform Inflammation - Driven Disease 2 FORWARD - LOOKING STATEMENTS This presentation contains "forward - looking statements" Fo
Inmune Bio, a clinical-stage biotechnology company, presents an overview of its strategy to develop innovative immunotherapies focusing on innate immune dysfunction. They emphasize their late-stage pipelines, particularly CORDStrom and XPro, which target rare pediatric diseases and Alzheimer's. The company's sessions highlight expected key regulatory milestones and challenges ahead, reiterating inherent uncertainties in their forward-looking statements. Participants were also alerted to the risks linked to funding and operational capabilities.
Read more →INMB▲ +5.8%on this news
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
INmune Bio Inc. announced its financial results for Q3 2025, highlighting advancements in its clinical programs, including CORDStrom™ and INKmune™. The company is focused on leveraging its platforms to develop treatments targeting the innate immune system. Despite positive developments, the company acknowledges the inherent risks in clinical trials and regulatory approvals.
Read more →INMBINmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday
INmune Bio Inc. will report its third quarter 2025 financial results on October 30, 2025, during a scheduled conference call at 4:30 PM ET. The company specializes in developing treatments targeting the innate immune system and is currently involved in multiple clinical trials, including promising programs for cancer and genetic disorders. The conference call will provide insights into the company’s financial status and ongoing research initiatives.
Read more →INMBINmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
INmune Bio Inc. announced that it will host a conference call on October 30, 2025, to discuss its third quarter financial results and provide a corporate update. The call is set to occur at 4:30 PM Eastern Time and will include various details about the company's current clinical programs. Investors and stakeholders can participate via a dial-in number or through a live audio webcast. The company focuses on developing treatments aimed at the innate immune system.
Read more →INMBINmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
INmune Bio, Inc. will have its CEO, David Moss, participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22-23, 2025. The panel will focus on the company's CORDStrom™ platform, aimed at treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). The event will take place at the Hard Rock Hotel in New York City, providing opportunities for networking and discussions on rare disease treatments.
Read more →INMBINmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
INmune Bio has submitted the results of its Phase 2 MINDFuL trial for XPro™ in early Alzheimer's disease to npj Dementia. Although the trial did not meet its primary endpoint, a subgroup analysis showed promising results for patients with high inflammatory burden. The company is optimistic about advancing to the next phase of clinical trials, pending regulatory feedback.
Read more →INMBINmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
INmune Bio has successfully completed its first commercial pilot-scale manufacturing run of CORDStrom™, a therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). This achievement, realized at the Cell and Gene Therapy Catapult in the UK, supports the company's timeline for regulatory submissions, including a Marketing Authorization Application in the UK and a Biologics License Application in the US in 2026. The therapy has shown positive results in clinical trials, addressing significant unmet needs for RDEB patients.
Read more →INMBINmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes
INmune Bio Inc. reported its financial results for Q2 2025 and provided a business update, highlighting advancements in its XPro product platform. Clinical data suggested XPro's effects were statistically significant compared to placebo, potentially aiding in neuroinflammatory conditions. The company also noted developments in its CORDStrom platform, aimed at treating complex inflammatory diseases. Despite positive trends, INmune Bio faces uncertainties regarding trial outcomes and regulatory approvals moving forward.
Read more →INMB▲ +11.5%on this newsshared move
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
INmune Bio's Phase I/II CaRe PC trial of INKmune™ in metastatic castration-resistant prostate cancer has successfully met its endpoints and is now closed to enrollment. The treatment showed a strong safety profile and significant effectiveness in activating NK cells, with some patients experiencing tumor reduction. The company plans to advance to a randomized Phase 2b trial.
Read more →INMBINmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
INmune Bio Inc., a clinical-stage biotechnology company, announced it will host a conference call on August 7th, 2025, to report its financial results for the second quarter of 2025 and provide a corporate update. The call will include information on ongoing clinical trials and company developments. INmune Bio is focused on developing treatments for chronic inflammatory diseases and cancer, utilizing innovative platforms such as DN-TNF and INKmune.
Read more →INMB▲ +8.6%on this newsshared move
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
INmune Bio Inc. announced the upcoming release of a video detailing findings from the Phase 2 MINDFuL trial of XPro™, a selective TNF inhibitor. The video will be published following the Alzheimer's Association International Conference and will provide insights into the trial's design and results. The trial demonstrated potential benefits in slowing cognitive decline in early-stage Alzheimer's patients.
Read more →INMBINmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro at the Alzheimer's Association International Conference Boca Raton
INmune Bio is set to present additional findings from its Phase 2 MINDFuL trial regarding XPro, a selective TNF inhibitor, at the Alzheimer's Association International Conference in Toronto. The trial, which included 208 early-stage Alzheimer's participants, showed promising results in some clinical measures despite not meeting its primary endpoint. The data indicates potential benefits in a specific subpopulation of patients with amyloid-beta pathology. Experts involved in the trial express optimism about the implications of these results for treating neuroinflammation in Alzheimer's disease.
Read more →INMB▼ -56.7%on this news
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
INmune Bio, Inc. announced the closing of a registered direct offering that raised approximately $19 million by selling 3,000,000 shares at $6.30 each. The funds will be used for working capital and general corporate needs. The offering was conducted under Nasdaq rules and was managed by A.G.P./Alliance Global Partners. INmune Bio focuses on developing therapies targeting the innate immune system to address various diseases, including Alzheimer's and cancer.
Read more →INMB▼ -56.7%on this newsshared move
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro in Early Alzheimer's Disease In the Phase 2 MINDFuL trial of XPro in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the mo
INmune Bio reported that its Phase 2 MINDFuL trial of XPro in early Alzheimer's Disease (AD) did not meet the primary cognitive endpoint in the modified intent-to-treat population. However, a defined subgroup of amyloid-positive patients with inflammation biomarkers showed significant cognitive benefits. Treatment was safe and well-tolerated, and findings will be further analyzed and presented at the upcoming Alzheimer's Association International Conference. INmune Bio plans to submit for Breakthrough Therapy designation based on these results.
Read more →INMB▼ -15.1%on this news· ran to -63% by day 1shared move
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Boca Raton, Florida
INmune Bio, Inc. has announced a registered direct offering of approximately $19 million, priced at $6.30 per share. The offering involves 3 million shares sold to institutional investors and is expected to close around June 30, 2025. The funds raised will be utilized for working capital and general corporate purposes. INmune Bio focuses on developing therapies targeting the innate immune system, with several product candidates in ongoing clinical trials.
Read more →INMB▼ -14.8%on this news· ran to -72% by day 3shared move
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th Company to host a conference call to discuss results at 8:00am EDT on
INmune Bio Inc. will announce the top line results from its Phase 2 MINDFuL trial focused on early Alzheimer's Disease on June 30, 2025. This international trial aims to assess the efficacy of XPro, a next-generation TNF inhibitor, in patients with early evidence of neuroinflammation. A conference call is scheduled for the same day to discuss the results, aiming to engage investors and the wider healthcare community. The study will evaluate cognitive endpoints to understand the drug's impact on patient health.
Read more →INMBXPro Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer's Disease: Supported by Department of Defense XPro Treatment Post-TBI Prevents Short- and Long-Term Alzheimer's-like
INmune Bio, Inc. reported positive findings from a study on XPro (XPro1595), an innovative treatment aimed at addressing Alzheimer's disease pathology following traumatic brain injury (TBI). Presented at the Keystone Symposia, the research demonstrated that XPro effectively reduces amyloid deposition and improves brain function in animal models. The study highlights the critical link between TBI, neuroinflammation, and Alzheimer's, suggesting that targeting related pathways may mitigate disease progression. This collaboration could pave the way for significant advancements in treating TBI-related cognitive decline.
Read more →INMB▼ -7.8%on this news
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
INmune Bio Inc. has announced its attendance at the 2025 RBC Capital Markets Global Healthcare Conference, taking place on May 20-21, 2025. The company will participate in a fireside chat and conduct one-on-one virtual meetings. INmune Bio is focused on developing treatments that target the innate immune system, with several products in clinical trials for conditions including Alzheimer's disease and cancer. However, these products are not yet FDA-approved, highlighting the uncertainties associated with their development.
Read more →INMBINmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update Conference Call Today at 4:30pm
INmune Bio Inc. released its financial results for Q1 2025 and provided a business update on its product platforms. The company is developing innovative therapies through its DN-TNF platform, showcasing their potential benefits for treating neurologic diseases and chronic inflammatory conditions. A conference call is scheduled for later today to discuss these updates in detail. Investors are reminded that ongoing clinical trials carry no guaranteed outcomes, especially regarding FDA approvals.
Read more →INMBINmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th Boca Raton, Florida
INmune Bio Inc. will host a conference call on May 8th, 2025, to discuss its first quarter financial results for the period ending March 31, 2025. The call will also provide a corporate update and is accessible via dial-in and audiocast. INmune Bio focuses on developing treatments for diseases such as Alzheimer's and cancer, with several product candidates in clinical trials. However, there remain significant uncertainties about the outcomes of these trials and necessary funding.
Read more →INMBINmune Bio Receives Favorable Patentability Opinion for CORDStrom Platform Technology Boca Raton, Florida, US
INmune Bio Inc. has received a favorable patentability opinion from the USPTO for its CORDStrom platform technology, which focuses on pooled, culture-expanded human umbilical cord-derived mesenchymal stromal cells. This opinion confirms the novelty and industrial applicability of INmune's claims, paving the way for potential IP exclusivity until at least 2045. Additionally, recent Phase 2 trial data suggest improvements in pain and skin integrity among patients. The company aims to expedite the patent process through the Patent Prosecution Highway.
Read more →INMBINmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom Manufacturing for Commercial Readiness Stevenage, UK, and Boca Raton, Florida, US
INmune Bio has announced a partnership with the Cell and Gene Therapy Catapult to scale up the manufacturing of CORDStrom, a therapy targeting recessive dystrophic epidermolysis bullosa (RDEB). This collaboration will leverage CGT Catapult's facilities to aid in producing cell therapies more efficiently. The initiative follows positive outcomes from recent clinical trials of CORDStrom, highlighting its potential to benefit children with severe RDEB. Additionally, INmune Bio plans to expand production for other therapies within this facility, emphasizing a commitment to addressing pressing healthcare challenges.
Read more →INMB▲ +11.5%on this newsshared move
ALZHEIMER'S DISEASE (AD) AND INFLAMMATION: BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS FROM A PHASE - 2 STUDY OF XPRO1595 IN EARLY AD Parris Pope 1 , Therese Blomberg 1 , Kim A Staats 1 , Sarah Barnum 2 , Judith Ja
The MINDFul study is a Phase 2 trial assessing XPro1595 in patients with early Alzheimer's disease and biomarkers of immune dysfunction. The trial aims to evaluate cognitive benefits over a 24-week period, with preliminary data indicating successful enrollment of a well-characterized patient cohort. Notably, XPro1595 targets immune system dysfunction, a recognized contributor to Alzheimer's pathogenesis. However, results from the study will not be available until June 2025, which introduces the potential for delayed insights on the drug's effectiveness.
Read more →INMBINmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida
INmune Bio Inc. presented baseline demographics and disease profiles for participants in its MINDFuL Phase II study at an Alzheimer's conference in Vienna. The study involves 208 patients diagnosed with mild cognitive impairment or early Alzheimer's and examines cognitive scores before and after treatment with XPro. Enrollment data reveals a predominance of participants who are APOE 4 carriers and meet multiple inflammation biomarker criteria. Full data results are anticipated by June 2025, although concerns about a high screen failure rate persist.
Read more →INMBINmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update Company to Host Conference Call Today, March 27, at 4:30pm
INmune Bio Inc. has announced its financial results for the year ended December 31, 2024, alongside a business update detailing its ongoing product developments. The company's leading projects, XPro1595, CORDStrom, and INKmune, aim to address serious diseases through innovative therapeutic solutions. While INmune shows promise with these advancements, challenges persist due to the lack of FDA approvals and a decrease in cash reserves. The company is set to host a conference call to discuss these developments further.
Read more →INMBINmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on
INmune Bio Inc. has announced plans to report its fourth quarter 2024 financial results and provide a corporate update during a conference call scheduled for March 27, 2025. The company, focused on inflammation and immunology therapies, will discuss its financial performance and ongoing clinical programs, including trials for Alzheimer's disease and cancer treatments. Participants can access the call via a designated phone number or through a live audio webcast. In the lead-up to this event, the company emphasizes the importance of transparency in its operations and future prospects.
Read more →INMBINmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
INmune Bio Inc. announced it will host a conference call on March 27, 2025, to discuss its financial results for the fourth quarter of 2024 and provide a corporate update. The company, which focuses on addressing diseases through its innovative therapies targeting the innate immune system, has multiple product candidates in clinical trials. However, as highlighted in their forward-looking statements, the outcomes of these trials and potential FDA approvals remain uncertain.
Read more →INMBINMB Nasdaq In vivo activation of mlNK cells with INKmune Preliminary results from a phase I/II trial in metastatic, castration - resistant prostate cancer Mark Lowdell CSO INmuneBio Inc INMB Nasdaq Innate Killer Summit
INmuneBio Inc. announced promising preliminary results from a phase I/II trial of INKmune, targeting metastatic, castration-resistant prostate cancer. The trial demonstrated successful in vivo activation of mlNK cells with no serious adverse effects reported after multiple patient infusions. The positive outcomes indicate further potential for the treatment to convert conventional NK cells into a more effective form capable of attacking tumors. The trial is currently enrolling patients for continued research.
Read more →INMB▲ +10.7%on this news
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer Medical review of Phase 1 cohorts demonstrated no safety issues Data to be presented at the 10 th Annual Innate Killer Summit, March 3-5
INmune Bio has announced the opening of a Phase II high dose cohort for its INKmune trial, targeting men with metastatic castration-resistant prostate cancer (mCRPC). Following the completion of the third and highest dose cohort in Phase I, the Scientific Review Committee has unanimously approved the initiation of enrollment for all Phase II cohorts. Early data has shown promising immunological effects of INKmune therapy, which converts patients' NK cells into tumor-killing memory-like cells. The trial will be featured at the upcoming Annual Innate Killer Summit in San Diego.
Read more →INMBCorporate Presentation Inflammation & Immunology Platforms XPro / CORDStrom / INKmune INMB Nasdaq February 2025 v19 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking s
INMB presented forward-looking information about its inflammatory and immunology platforms, particularly highlighting CORDStrom, which has demonstrated clinical benefit in treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). The BLA submission for CORDStrom is anticipated by December 2025 following successful trial outcomes. INMB's various programs, including XPro and INKmune, are scheduled for data disclosures in 2025, underscoring its commitment to addressing significant medical needs in rare diseases and conditions.
Read more →INMBINmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) The Company reports results of a double-blinded
INmune Bio plans to submit a Biologics License Application (BLA) to the FDA for CORDStrom, aimed at treating Recessive Dystrophic Epidermolysis Bullosa (RDEB) in pediatric patients. Supported by data from the MissionEB clinical trial, CORDStrom demonstrated notable efficacy and was well tolerated among participants. The company sees a significant opportunity to address the unmet medical needs of approximately 4,500 children diagnosed with severe RDEB. Additionally, CORDStrom has received both rare pediatric disease and orphan drug designations, further enhancing its development prospects.
Read more →INMBINmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration Hospital Boca
INmune Bio Inc. has announced that the first patient has been treated in the Phase II portion of its clinical trial for metastatic prostate cancer at the West Los Angeles Veterans Administration Hospital. This trial aims to assess the safety and efficacy of its investigational therapy, INKmune, which targets natural killer cells to combat cancer. The trial follows the guidelines established by the Cleland-Dole Act, which emphasizes improving prostate cancer care for veterans. With the capacity to enroll up to 30 patients, the trial represents a significant step in exploring innovative cancer therapies for veterans.
Read more →INMBINmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
INmune Bio Inc. has announced the full repayment of their term loan with Silicon Valley Bank, which amounted to $15 million. This repayment is expected to reduce their quarterly cash burn and improve their financial position ahead of the upcoming Phase 2 trial data in Alzheimer's Disease. The company reported an over-enrollment in their AD02 Trial, with cognitive data expected in Q2 2025, indicating ongoing commitment to their clinical development efforts.
Read more →INMBINmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease Boca Raton, Florida
INmune Bio Inc. announced that it has completed the enrollment of 208 patients in its Phase 2 trial for Early Alzheimer's Disease, known as the AD02 trial. This global trial focuses on patients with neuroinflammation, and the company plans to release top line cognitive results by the second quarter of 2025. The overenrollment in the trial is seen as a major accomplishment, highlighting the commitment of the team and the potential impact of their treatment approach targeting neuroinflammation.
Read more →INMBInflammation and Immunology Repair Two Platforms in the Clinic: XPro and INKmune INMB Nasdaq November 2024 v4b 2 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking stat
INMB is advancing its therapies with two platforms: XPro for Alzheimer's disease and INKmune for cancer treatment. XPro targets Alzheimer’s as an immunologic disorder, with Phase 2 results anticipated in Q2 2025. In parallel, INKmune seeks to develop memory-like NK cells for metastatic castrate-resistant prostate cancer. Though the platforms are promising, the company acknowledges inherent risks in its forward-looking statements, including uncertainties in operational results and investment outcomes.
Read more →INMBINmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
INmune Bio Inc. announced its financial results for Q3 2024, highlighting significant progress in its clinical-stage immunotherapy treatments. The results disclose increased operating expenses and a net loss, yet showcase advancements in their drug platforms, including XPro and INKmune. Both drug candidates are under clinical trials, with potential applications in treating neurological diseases and various cancers. The company continues to focus on harnessing the innate immune system for innovative treatment options.
Read more →INMB▲ +13.7%on this newsshared move
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials" Webinar to be Held on
INmune Bio Inc. is hosting a webinar on November 7, 2024, to discuss the EMACC tool for measuring cognitive changes in early Alzheimer's disease trials. This presentation follows the data to be showcased at the CTAD 2024 conference. The EMACC tool is designed to provide a more accurate assessment of cognitive change compared to traditional methods. However, as INmune Bio is still conducting early-stage clinical trials, there remain uncertainties regarding product approval and future outcomes.
Read more →INMBINmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro Promotes Remyelination Data from Animal Model Study Demonstrate XPro converts microglia from a demyelinating cell to a remyelinating cell Multi-yea
INmune Bio, Inc. has announced the publication of a key study in Cell Reports highlighting that XPro1595 promotes remyelination in a model of demyelinating disease. Conducted under Dr. Leslie Probert, the study emphasizes microglia's role in neuron communication and proposes blocking soluble TNF as a treatment strategy. INmune Bio anticipates reporting cognitive trial results for early Alzheimer’s patients soon. This research underlines the drug's potential impact on neurodegenerative diseases.
Read more →INMBINmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on
INmune Bio Inc. announced it will report its third quarter financial results on October 31, 2024, during a conference call at 4:30 PM ET. The biotechnology company, focused on developing treatments for Alzheimer’s Disease and cancer, is actively recruiting patients for clinical trials. INmune has two significant product platforms in development, further enhancing its research footprint. The report will also provide a corporate update, which may be of interest to investors and stakeholders.
Read more →INMBINmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit Boca Raton, Florida
INmune Bio Inc. announced its participation in the Maxim Healthcare Virtual Summit scheduled for October 15-17, 2024. The company, engaged in developing treatments targeting neuroinflammation for Alzheimer's Disease, plans to showcase its innovations through a fireside chat and virtual meetings. Currently, INmune is conducting clinical trials for its Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform and the Natural Killer Cell Priming platform. Despite the promising work, the company faces uncertainties related to clinical outcomes and regulatory approvals.
Read more →INMBINmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
INmune Bio Inc. has successfully completed enrollment for its Phase 2 clinical trial focusing on early-stage Alzheimer's disease, known as the AD02 trial. The trial aims to evaluate the efficacy of XPro™ on patients with elevated biomarkers of neuroinflammation. By concluding enrollment with 201 patients, the company anticipates a modest over-enrollment which may enhance the trial's statistical power. The trial is a key step in the company's efforts to develop treatments that target neuroinflammation in Alzheimer's disease.
Read more →INMBINKmune Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
INmune Bio Inc. announced positive early results from its Phase I/II trial of INKmune, a NK cell therapy designed for men with metastatic Castration-Resistant Prostate Cancer (mCRPC). The initial cohort demonstrated an excellent safety profile, with all patients receiving treatment as outpatients. Notably, the treatment showed an increase in activated NK cells in two of the three participants. The trial continues with subsequent cohorts expected to begin soon, following the successful dosing of the last patients in the second cohort.
Read more →INMBINmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
INmune Bio Inc. announced promising results from an interim analysis of its AD02 Phase II clinical trial for Alzheimer's disease. The analysis demonstrated a strong correlation between the Early AD/MCI Alzheimer's Cognitive Composite (EMACC) and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), confirming the suitability of EMACC as a primary endpoint. The findings indicate that EMACC can effectively gauge cognitive changes in early Alzheimer’s patients and offers enhanced precision over traditional measures. The company looks forward to completing enrollment shortly and plans to release topline data in approximately six months.
Read more →INMBINmune Bio Announces $13.0 Million Registered Direct Offering Boca Raton, Florida
INmune Bio Inc. has announced a registered direct offering of approximately $13.0 million, primarily targeting institutional investors and company insiders. The offering includes the sale of over 2.34 million shares of common stock along with warrants that will commence six months after issuance. Proceeds from the offering are intended for working capital and general corporate purposes. The company is active in developing treatments that utilize the innate immune system to treat various diseases, including Alzheimer's and cancer, but remains reliant on ongoing clinical trials.
Read more →INMB▼ -7.1%on this news
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference Boca Raton, Florida
INmune Bio Inc. has announced its participation in several investor conferences, including the Baird 2024 Global Healthcare Conference in Boca Raton, Florida. The company is focused on developing treatments harnessing the innate immune system and is currently conducting clinical trials for their product platforms. Notably, their XPRO1595 is being tested for Mild Alzheimer's disease, while INKmune aims to treat various cancers. However, these products have yet to receive FDA approval, and the company faces uncertainties regarding funding and future operational capabilities.
Read more →INMB▼ -7.9%on this news
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday
INmune Bio Inc. will host a conference call on August 1, 2024, to discuss its second quarter financial results and corporate updates. The company focuses on harnessing the innate immune system to develop treatments for various diseases, with products currently being tested in clinical trials. While some positive developments are being pursued, the company faces significant regulatory and funding challenges.
Read more →INMB▼ -7.9%on this news
INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, August 1, at 4:30pm
INmune Bio Inc. has released its financial results for Q2 2024 and provided an update on its clinical trials. The company continues to develop therapies that leverage the innate immune system, focusing on products like XPro and INKmune. Despite a reported net loss and a decrease in cash reserves, INmune Bio is actively progressing with its clinical trials aimed at treating various diseases. The company will host a conference call to discuss these results and future milestones.
Read more →INMBINmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
INmune Bio Inc. presented compelling findings from a Phase 1b study of XPro™, revealing its significant dose-dependent effects on synaptic proteins in Alzheimer's patients. The analysis highlights XPro's role in modulating immune system functions critical for neuron communication, suggesting its potential in treating cognitive impairment associated with Alzheimer's disease. The company is currently conducting a Phase 2 trial to evaluate the cognitive benefits of XPro™, with results expected in early 2025.
Read more →INMBINmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
INmune Bio Inc. has announced a conference call scheduled for August 1, 2024, to discuss its financial results for Q2 2024 and provide a corporate update. The call, which can be accessed via live audio webcast, will cover developments in the company's clinical trials focusing on therapies for conditions such as Mild Alzheimer's disease and cancer. The company emphasizes its commitment to exploring novel treatments that utilize the innate immune system. However, it cautions that the outcomes of its ongoing clinical trials are uncertain, with various risks mentioned regarding future success and funding.
Read more →INMBINmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
INmune Bio Inc. has announced the publication of a pivotal study in the Journal for ImmunoTherapy of Cancer, co-authored by its CSO, Mark Lowdell, detailing the characteristics of memory-like natural killer (mlNK) cells in cancer immunotherapy. The research showed that mlNK cells generated from cancer patients exhibit enhanced cytotoxicity against tumors comparable to those generated from healthy volunteers, paving the way for innovative treatments in various cancers. Additionally, the study highlighted how INKmuneTM priming increases the functionality of these NK cells in challenging tumor environments. This research is expected to bolster ongoing clinical trials of INKmuneTM for metastatic castration-resistant prostate cancer.
Read more →INMB▲ +19.2%on this news
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary en
INmune Bio, Inc. has completed a blinded interim analysis of its Phase II Alzheimer's Disease trial, confirming that the study's design and sample size calculations are appropriate. Conducted by a third-party organization, the analysis indicated no need for alterations, affirming the robustness of the primary endpoint, the Early Mild Alzheimer's Cognitive Composite (EMACC). The findings are promising for the ongoing investigation of XPro, a treatment targeting neuroinflammation in Alzheimer's patients.
Read more →INMBINmune Bio Inc. to Join Russell 3000 Index Boca Raton, Florida
INmune Bio Inc. has announced its inclusion in the Russell 3000 Index effective July 1, 2024, as part of the annual reconstitution. The company aims to leverage this achievement to enhance its visibility within the investment community and to broaden its shareholder base. The Russell indexes are crucial for institutional investors and asset managers, which may foster greater investment interest in INmune Bio. This milestone is a reflection of the company's efforts in developing treatments for various conditions, including Early Alzheimer's and cancer.
Read more →INMBINmune Bio Inc. to Join Russell 3000 Index
INmune Bio Inc. is set to join the Russell 3000 Index on July 1, 2024, following its inclusion in the preliminary list of additions. This membership signifies a higher market visibility and broader shareholder base for the company, which is focused on developing immunology and inflammation treatments. CEO Dr. Raymond J. Tesi highlighted the achievement as a testament to the team's dedication. Russell indexes are widely used as benchmarks by investment managers, reflecting the company's growing importance in the investment community.
Read more →INMBINmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
INmune Bio Inc. reported its financial results for the first quarter of 2024, showing a net loss of $11.0 million. The company provided updates on several clinical programs, highlighting progress in Alzheimer's and cancer treatments. The AD02 trial is on track for final enrollment by mid-2024, with data anticipated afterward. INmune Bio also successfully raised $14.5 million in equity, indicating strong investor interest despite a rise in expenses and net losses.
Read more →INMBINmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
INmune Bio Inc. will report its financial results for the first quarter of 2024 on May 9, 2024, at 4:30 PM EDT. The company will discuss the performance of its clinical programs, including its focus on immunology treatments. A conference call will be hosted for stakeholders to participate and learn about the corporate updates. This session signifies INmune's engagement with its investors regarding its developmental progress and future strategies.
Read more →INMBINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
INmune Bio Inc. has provided an update on two patients from its Phase 1b Alzheimer's trial who have received XPro™ under a compassionate use program for over three years. Both patients have shown stable cognitive function and report satisfaction with the treatment. Their primary care physicians confirmed that XPro™ has been well-tolerated without adverse reactions. The company continues its Phase 2 trial for Alzheimer's disease, aiming to validate these positive results.
Read more →INMBINmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Boca Raton, Florida
INmune Bio Inc. has successfully completed the first cohort and initiated the second cohort of its Phase 1/2 clinical trial for INKmune, a natural killer cell therapy aimed at treating metastatic castration-resistant prostate cancer (mCRPC). The company reports that nine doses have been administered without significant adverse events, allowing them to proceed following the Safety Review Committee's approval. The trial aims to demonstrate safety and determine optimal dosing for future studies. INKmune's ability to transform resting NK cells may provide a unique approach to enhance cancer treatment.
Read more →INMBINmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Boca Raton, Florida
INmune Bio Inc. has announced a registered direct offering of approximately $9.7 million, priced at $9.84 per share based on the last five days' closing prices. The offering is intended to fund the company's ongoing Phase 2 clinical trials for Alzheimer's disease and metastatic castration-resistant prostate cancer. The closing of the offering is anticipated around April 29, 2024, subject to customary conditions. Notably, the warrants associated with this offering include an acceleration clause tied to positive trial data.
Read more →INMBINmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay Boca Raton, Florida
INmune Bio, Inc. has announced the successful completion of a 24-month stability validation for its product XPro, which is crucial for its phase III and commercial supply chain readiness. This stability validation allows the company to align its distribution strategies with established pharmaceutical practices. Additionally, the firm has developed a novel immunogenicity assay and filed a patent application to enhance the reliability of anti-drug antibody detection related to XPro. These developments are positioned to support INmune's ongoing clinical trials, particularly in treating Alzheimer's disease.
Read more →INMB▲ +26.9%on this newsshared move
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering Boca Raton, Florida
INmune Bio Inc. has announced a successful registered direct offering, raising approximately $4.8 million by selling 571,592 shares of its common stock. This offering involved significant participation from company officers, directors, and employees who collectively purchased about 20% of the offering. The proceeds will be utilized for ongoing clinical trials in Alzheimer’s disease and metastatic castration-resistant prostate cancer. Closing of the offering is expected on or around April 24, 2024, pending typical closing conditions.
Read more →INMBINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Res
INmune Bio, Inc. presented promising data on INB03 as a novel immune checkpoint modulator targeting soluble TNF in high-risk breast cancer at AACR 2024. The research indicates that INB03 decreases immunosuppressive proteins and enhances T cell infiltration, showing significant tumor growth reduction when combined with an anti-HER2 antibody. Additionally, MUC4 expression was identified as an independent biomarker for poor survival in TNBC, suggesting its potential role in guiding treatment decisions. The company plans to explore further clinical development and partnerships to advance INB03's use in oncology.
Read more →INMBINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update Company to Host Conference Call Today, March 28, at 4:30pm
INmune Bio Inc. reported its financial results for 2023, indicating a net loss increase compared to the previous year. The company continues to advance its clinical-stage immunology treatments, notably XPro and INKmune, which target various cancer types through unique mechanisms. Despite the promising innovations, financial metrics indicate declining cash reserves and mounting operational losses, highlighting the challenges faced in the biotech landscape. A conference call is scheduled for March 28, 2024, to discuss these results in detail.
Read more →INMBINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
INmune Bio Inc. has announced a conference call scheduled for March 28, 2024, to discuss its fourth quarter financial results and provide a corporate update. The company is focused on developing treatments that harness the innate immune system and is currently conducting clinical trials for its product platforms. However, none of its drug candidates have received FDA approval, and there are uncertainties regarding future funding and market conditions.
Read more →INMBINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
Dr. Mark Lowdell, CSO and Co-Founder of INmune Bio Inc. (NASDAQ: INMB), has received the ISCT Career Achievement Award in Cell and Gene Therapy, a recognition bestowed by the International Society for Cell & Gene Therapy. This award acknowledges Dr. Lowdell's exceptional contributions over a 30-year career in translational immunotherapy. He is noted for developing multiple cell-based therapies and has led significant advancements in manufacturing processes for immunotherapies. The award ceremony will take place on May 29, 2024, in Vancouver.
Read more →INMB▼ -5.4%on this news
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
INmune Bio has reported significant improvements in brain activity among Alzheimer's Disease patients following four weeks of treatment with XPro™, evidenced by increases in Alpha wave frequency and power. This pilot study confirms the effectiveness of XPro™ in enhancing EEG biomarkers, reinforcing earlier findings from a Phase 1 study. The company emphasizes the potential utility of EEG as a measure of cognitive engagement in ongoing research, which aims to assess the treatment's broader cognitive effects in a larger patient cohort.
Read more →INMBINmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
INmune Bio, Inc. will present a corporate update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The company's leadership, including CEO Dr. RJ Tesi and CFO David Moss, will be available for one-on-one meetings throughout the event. INmune Bio is focused on developing treatments targeting microglial activation and neuroinflammation related to Alzheimer's disease with its lead candidate, XPro1595. The company is also advancing other therapies for various cancers in clinical trials.
Read more →INMBINmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
INmune Bio, Inc. will participate in Baird's Biotech Discovery Series webcast on February 13, 2024. During the event, CEO RJ Tesi and other key scientists will discuss updates on their Phase II trial targeting Early Alzheimer's disease. The company aims to address neuroinflammation through its XPro™ therapy, which has shown positive effects in previous studies, including reduced levels of neurodegeneration and improved synaptic function.
Read more →INMB▼ -7.5%on this news
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program The Phase II clinical trial in patients with Alzheimer's disease with neuroinflammation is on track to complete enrollment mid-2024 with t
INmune Bio Inc. has announced that the FDA has lifted the clinical hold on its Alzheimer's disease program, allowing the Phase II clinical trial focusing on neuroinflammation to continue. The company projects that enrollment for this trial will conclude by mid-2024, with top-line data anticipated approximately six months thereafter. Following the completion of Phase II, INmune aims to engage in discussions with the FDA regarding the upcoming Phase III trial, expected to include sites in multiple regions including the U.S. and Europe.
Read more →INMBINmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer Boca Raton, Florida
INmune Bio, Inc. has announced the dosing of the first patient in its Phase 1/2 trial of INKmune for metastatic castration-resistant prostate cancer (mCRPC). The trial aims to evaluate the safety and effectiveness of INKmune, an out-patient therapy designed to activate the patient's own natural killer (NK) cells. The study's design includes a careful follow-up of patient responses to treatment, utilizing advanced techniques such as AI and PSA measurement to assess anti-tumor efficacy. With high hopes from experts involved, INKmune represents a potentially groundbreaking immunotherapy approach for mCRPC patients.
Read more →INMB▲ +8%on this news
INmune Bio Provides Update Regarding Global Alzheimer's Phase II Clinical Trial and Clinical Hold Issued by the United States FDA Enrollment in the Company's Phase II study using XPro TM to treat patients with Alzheimer'
INmune Bio has provided an update regarding its Phase II clinical trial for Alzheimer's treatment, specifying that enrollment is progressing well in sites outside the U.S. However, the trial is currently on clinical hold due to the FDA requesting additional information about long-term stability of the treatment XPro. The company is confident in addressing these queries before the year's end, asserting that the clinical hold will not affect overall trial timelines as recruitment is focused internationally.
Read more →INMBINmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium INB03 increases uptake of derux
INmune Bio, Inc. presented promising data suggesting that INB03 enhances the uptake of trastuzumab deruxtecan in HER2+ breast cancer with MUC4 expression at the San Antonio Breast Cancer Symposium. This combination potentially improves treatment efficacy, allowing lower doses of T-DXd. Preliminary findings indicate that INB03 may decrease resistance mechanisms linked to MUC4. However, the clinical trials for INB03 are still ongoing, and there are risks associated with achieving regulatory approval and positive patient outcomes.
Read more →INMBINmune Bio Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease Boca Raton, Florida
INmune Bio has received authorization from the European Medicines Agency to commence a Phase II clinical trial for XPro, focusing on early Alzheimer's disease in France and Spain. This trial expands upon the company's previous approvals in Poland and is part of a broader strategy for global clinical development. Early results from previous studies indicate that XPro effectively reduces neuroinflammation and improves cognitive function. The company emphasizes the importance of this trial in enhancing treatment options for patients with neurodegenerative conditions.
Read more →INMBINmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe The Company received regulatory approval to extend its Phase II trial of XPro in individuals with early Alzheimer's disease
INmune Bio Inc. announced the expansion of its Phase II clinical trial for XPro, targeting early Alzheimer's disease, after receiving regulatory approval in Poland. Additional approvals are anticipated from up to six more EU countries in the coming months. Previous trials demonstrated positive outcomes, including reductions in neuroinflammation and improvements in brain function. The company has also secured a cash refund of $2.8 million from an Australian R&D incentive, which will be reinvested into the clinical trial efforts.
Read more →INMBINmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update Company to Host Conference Call Today, November 1, at 4:30pm
INmune Bio Inc. announced its third-quarter 2023 financial results and updates on its clinical programs focused on immunology treatment by harnessing the innate immune system. The company highlighted progress on its DN-TNF platform and its innovative INKmune treatment, which is undergoing clinical trials for various cancers. Despite the advancements, the company acknowledged that its products have not yet received regulatory approval and are still in the early stages of clinical testing.
Read more →INMB▲ +7.8%on this newsshared move
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune Therapeutic Composition given Favorable Patentability Opinion by International Search Authority INmune Bio receives International Search Report and Writt
INmune Bio, Inc. has received a favorable patentability opinion from the International Search Authority for its proprietary INB16 cell line and INKmune therapeutic composition. This opinion confirms novelty, inventive step, and industrial applicability, suggesting strong potential for commercial use. The company plans to utilize this opinion to accelerate patent issuance and has successfully treated patients with hematological cancers using INKmune. This therapy may provide enhanced NK cell activity against resistant tumors.
Read more →INMB▲ +10.3%on this news
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
INmune Bio Inc. presented new biomarker and feasibility data from their Phase Ib study of XPro™ for Alzheimer’s disease at the CTAD conference. Significant findings include improvements in MRI gray matter microstructure and neuronal proteins associated with core AD pathologies. The company is currently enrolling Alzheimer’s patients in a global Phase II trial to further investigate the drug’s effects on neuroinflammation and associated cognitive function benefits.
Read more →INMBINmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
INmune Bio Inc. has announced a conference call scheduled for November 1, 2023, to discuss its third quarter 2023 financial results and provide a corporate update. The company, focused on novel treatments that leverage the innate immune system, aims to keep stakeholders informed about its progress. This call comes as INmune Bio continues its clinical trials for its product candidates, which target various diseases. However, forward-looking statements highlight uncertainties related to trial outcomes and regulatory approvals.
Read more →INMBINmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference Boca Raton, FL
INmune Bio Inc. has announced that its CEO, Dr. RJ Tesi, and CFO, David Moss, will participate in the upcoming Baird Global Healthcare Conference and H.C. Wainwright 25th Annual Global Investment Conference in September 2023. Both executives will be available for one-on-one meetings to discuss the company’s clinical-stage immunology therapies. The participation in these events emphasizes the company's commitment to its business strategy and investor relations.
Read more →INMBINmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer's Disease The authorization provides approval for t
INmune Bio, Inc. has received approval from the U.K. Medicines and Healthcare Products Regulatory Agency for a Phase 2 clinical trial involving XPro, aimed at treating early Alzheimer's disease. This trial will expand the current study, which is already enrolling patients in Australia and Canada, and takes place in a region known for its sophisticated medical community. Earlier Phase I trials demonstrated promising results, including significant reductions in neuroinflammation and improvements in brain function. The U.K. is considered an optimal location for these trials, given the high prevalence of Alzheimer's disease and supportive healthcare infrastructure.
Read more →INMBINmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update Company to Host Conference Call Today, August 7, at 4:30pm
INmune Bio Inc. has announced its financial results for Q2 2023, detailing a net loss of $6.5 million. The company is continuing with its clinical-stage immunology initiatives, particularly focusing on the DN-TNF platform. Upcoming trials include those for its product candidates targeting various cancers and neurological diseases. INmune emphasizes its mission to develop therapies that enhance the innate immune system, although significant uncertainties remain regarding regulatory approvals and clinical outcomes.
Read more →INMBINmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference Boca Raton, FL
INmune Bio Inc. announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for August 7-8, 2023. CEO RJ Tesi and CFO David Moss will present a corporate overview and will also be available for one-on-one meetings with attendees. The company focuses on developing treatments that leverage the innate immune system, with clinical trials ongoing for multiple product candidates targeting cancer, Alzheimer's disease, and treatment-resistant depression. However, these products have yet to receive FDA approval, and their trial outcomes remain uncertain.
Read more →INMBINmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
INmune Bio, Inc. has announced a conference call scheduled for August 7, 2023, at 4:30 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2023, and provide a corporate update. The clinical-stage biotechnology firm focuses on therapies that harness the innate immune system to tackle diseases such as cancer and Alzheimer's. Their product candidates are currently undergoing clinical trials, reflecting ongoing research endeavors in the biotech sphere.
Read more →INMB▼ -6.9%on this news
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
INmune Bio, Inc. is set to present the opening keynote at the 5th World Aging and Rejuvenation Conference in Frankfurt, Germany. CEO RJ Tesi will discuss innovative drug development strategies focused on treating chronic diseases associated with aging. The talk will highlight the use of neuroimaging biomarkers and the company's work on cognitive aging, differentiating it from Alzheimer’s disease. The event aims to address the key challenges in enhancing health span through advanced clinical trial methodologies.
Read more →INMB▲ +14.2%on this newsshared move
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
INmune Bio Inc. has announced promising data from a Phase 1b study indicating improvement in gray matter in Alzheimer's disease patients after treatment with their investigational drug XPro1595TM. The new findings, presented at the Alzheimer's Association International Conference in Amsterdam, highlight the effectiveness of the novel Cortical Disarray Measurement (CDM®) biomarker to assess changes in microstructural brain health. This analysis demonstrates a dose-dependent enhancement in gray matter metrics, correlating with key Alzheimer's biomarkers. The results support the utility of diffusion MRI as a noninvasive tool in Alzheimer's clinical trials.
Read more →INMBINmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro Promotes Remyelination by Affecting Astroglial and Microglial Biology Neutralizing soluble TNF wi
INmune Bio Inc. presented promising data at the 16th European Meeting on Glial Cells in Health and Disease, showing that their drug XPro effectively promotes remyelination by influencing astrocyte and microglial activity. The findings suggest a shift in understanding the roles of glial cells in neuroinflammation, revealing that activation of these cells is beneficial for repairing myelin sheaths. Although the results are encouraging, INmune Bio acknowledges that their therapies, including XPro, are still in the early clinical trial phases and face potential risks related to funding and regulatory approvals.
Read more →INMBINmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
INmune Bio Inc.'s Chief Scientific Officer, Dr. Mark Lowdell, will present a lecture at the ISCT in Paris on May 31. His talk will focus on the advancements in Natural Killer (NK) cell therapies, specifically discussing the company's proprietary INKmune™ platform, which primes NK cells for improved cancer treatment. The acceptance of their IND application for a prostate cancer trial further indicates INmune Bio's ongoing commitment to innovative cancer therapies. The research emphasizes the potential of INKmune™ to enhance the effectiveness of NK cells without traditional cytokine risks.
Read more →INMB▼ -5.5%on this news
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM INMB Webinar Phase I/II Trial of INKmune in Metastatic Castration - Resistant Prostate Cancer FORWARD LOOKING STATEMENTS This presentation contains "forward - looking stat
The article discusses a recent webinar presentation detailing the Phase I/II trial of INKmune, an innovative NK cell therapy aimed at treating metastatic castration-resistant prostate cancer (mCRPC). Led by experts from UCLA and INmune Bio, the discussion highlighted significant aspects of the therapy's mechanism of action, and the potential benefits of activating patients' own immune systems to combat resistant cancer cells. Furthermore, the presentation raised important considerations regarding the trial design and the uncertainties surrounding the development and commercialization processes for this treatment.
Read more →INMBINmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune , a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer Represents First Ever Natural Killer Immunothe
INmune Bio, Inc. announced FDA approval for its IND application for INKmune, a natural killer cell immunotherapy, to conduct a Phase I/II trial targeting metastatic castration-resistant prostate cancer (mCRPC). This marks a significant milestone as it represents the first natural killer immunotherapy trial aimed at mCRPC patients, a demographic with few current treatment options. The trial is set to enroll 30 patients, aiming to evaluate both the short and long-term safety and therapeutic efficacy of the treatment. Initial patient enrollment is anticipated in the latter half of 2023.
Read more →INMB▼ -5.6%on this newsshared move
INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update Company to Host Conference Call Today, May 3, at 4:30pm
INmune Bio Inc. announced its financial results for the first quarter of 2023, revealing a reduced net loss of approximately $6.5 million compared to $6.9 million in the same quarter last year. The company reported that its research and development expenses were slightly lower than the previous year and it successfully obtained $6.5 million in rebates from research programs in Australia and the UK. INmune Bio plans to discuss these results and upcoming milestones during a conference call scheduled for May 3, 2023, at 4:30 PM ET.
Read more →INMBINmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
INmune Bio, Inc. announced a conference call scheduled for May 3, 2023, to discuss their first quarter financial results and provide a corporate update. The company, which focuses on developing treatments that leverage the innate immune system, is currently conducting clinical trials on several product candidates. However, uncertainties around FDA approvals and the need for additional funding pose risks to its progress. The results of the call may give insight into the company’s financial health and strategic direction.
Read more →INMBXPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer's Disease TNF is involved in the development of Alzheimer's Disease pathology following traumatic brain injury and is prevented by neutralization of so
INmune Bio, Inc. announced promising pre-clinical data regarding its product XPro1595, showing that it may prevent amyloid pathology related to Alzheimer's disease following traumatic brain injury (TBI) in a mouse model. The research, conducted by Virginia Commonwealth University and Barrow Neurological Institute, highlights soluble TNF's role in developing Alzheimer's pathology post-TBI. The results suggest that early intervention with XPro1595 could lead to better outcomes for the elderly at risk of developing Alzheimer's due to TBI. The findings were presented at the AD/PD 2023 International Conference.
Read more →INMB▲ +6.7%on this news
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03 Two presentations show targeting high-risk MUC4 ex
INmune Bio, Inc. will present preclinical data at the 2023 AACR Annual Meeting, illustrating the efficacy of INB03 in targeting MUC4 expression in high-risk breast cancer. The study reveals that INB03 may enhance the effectiveness of immunotherapies used in treating HER2-positive and triple-negative breast cancers by reversing certain resistance mechanisms. Roxana Schillaci, the lead scientist, emphasizes the potential of this approach to improve therapy responses in women suffering from relapsing breast cancer. The findings could offer new therapeutic options for a patient population characterized by poor survival rates due to treatment-resistant disease.
Read more →INMB▲ +7%on this news
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
INmune Bio, Inc. announced the submission of an Investigational New Drug (IND) application for INKmune, aimed at treating metastatic castration-resistant prostate cancer (mCRPC). The trial will enroll approximately 30 patients across multiple U.S. medical centers, testing the safety and efficacy of the therapy. INKmune represents a potential new option that could help patients avoid cytotoxic chemotherapy. However, the success of the trial is not guaranteed, as it is still in the early stages and FDA consultation may be required.
Read more →INMBI N M B IN V E S T O R PRES E NT A TIO N March 2023 H A R N E SS I N G T H E P O W E R O F T H E I NN A T E I MM U N E S Y S T E M Two Therapeutic Platforms: XPro and INKmune He l p Rep a ir Inn a te Immune D ysfunction
INmune Bio's March 2023 investor presentation highlighted its two therapeutic platforms, XPro and INKmune, targeting innate immune system dysfunction in various diseases, including Alzheimer's and cancer. XPro focuses on selectively inhibiting soluble TNF to reduce neuroinflammation, which has seen promising results in initial clinical trials. INKmune aims to enhance the anti-tumor activity of natural killer cells. However, the company noted the inherent uncertainties related to their forward-looking statements, as both platforms are still in clinical trial stages and not yet FDA approved.
Read more →INMBINmune Bio, Inc. Announces 2022 Results and Provides Business Update Company to Host Conference Call Today, March 2, at 4:30pm
INmune Bio, Inc. has announced its financial results for the year 2022, reporting a net loss of approximately $27.3 million, which is an improvement over the previous year's loss. The company also provided a business update, highlighting a focus on developing treatments aimed at harnessing the innate immune system for various diseases, including prostate cancer. Additionally, they are set to host a conference call to discuss these results and future milestones. Their current cash position is approximately $52.2 million, supporting their ongoing research initiatives.
Read more →INMBINmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
INmune Bio, Inc. has announced it will host a conference call on March 2, 2023, at 4:30 PM ET to discuss its fourth quarter and full-year 2022 results. The company, which focuses on developing treatments using the innate immune system, is currently conducting clinical trials on its product candidates. These candidates target various diseases, including cancer and Alzheimer's. The announcement indicates the company's commitment to transparency with its stakeholders about its progress and future plans.
Read more →INMB▲ +10.1%on this news
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
INmune Bio, Inc. has announced that it received approximately $6.4 million in research and development rebates from Australia and the United Kingdom. This funding will be utilized to enhance recruitment and enrollment in its ongoing Phase 2 Alzheimer's Disease trial in Australia and Canada. The company emphasizes that these non-dilutive funds will support its clinical programs and facilitate further international expansion. Moreover, the CFO indicated plans to continue collaborating with the FDA for upcoming U.S. trials.
Read more →INMB▲ +9.3%on this news
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy Boca Raton, Florida
INmune Bio, Inc. has announced promising pre-clinical data supporting its novel Dominant-Negative TNF (DN-TNF) biologic for treating Duchenne Muscular Dystrophy (DMD). The data show significant reductions in muscle damage and noteworthy muscle regeneration in pre-clinical models. The company aims to advance this unique therapeutic approach with a dedicated subsidiary, focusing on DMD indications while maintaining attention on its core CNS programs. Despite the positive results, the therapy is still in early clinical stages, and FDA approval remains uncertain.
Read more →INMBINmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer's Disease XPro1595 d
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer's Disease XPro1595 decreases development of amyloid beta and tau following TB
Read more →INMB▲ +6.6%on this news· ran to +21% by day 3
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune Boc
Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (
Read more →INMBINmune Bio, Inc. Reports Combination Therapy with INB03 Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer Neutralizing soluble TNF with INB03 overcomes resistance to trastuzumab-deruxt
INmune Bio, Inc. Reports Combination Therapy with INB03 Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer Neutralizing soluble TNF with INB03 overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing Combination therapy of INB03 and
Read more →INMBINmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer's Disease Treatments INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15 th CTAD
Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer's Disease Treatments INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD conference in San Francisco November 29th to Boca Raton, Florida, Nov. 29,
Read more →INMBINmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease
BOCA RATON, FL., Nov. 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that Health Canada has issued
Read more →INMBC O R P O R A T E P A R T I C I P A N T S David Moss, Chief Financial Officer RJ Tesi, Chief Executive Officer CJ Barnum , Head of Neuroscience Mark Lowdell, Chief Scientific Officer C O N F E R E N C E C A L L P A R T I
C O R P O R A T E P A R T I C I P A N T S David Moss, Chief Financial Officer RJ Tesi, Chief Executive Officer CJ Barnum, Head of Neuroscience Mark Lowdell, Chief Scientific Officer C O N F E R E N C E C A L L P A R T I C I P Mayank Mamtani, B. Riley Securities Daniel Carl
Read more →INMB▼ -7%on this newsshared move
INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update Company to Host Conference Call Today, November 2, at 4:30pm
Inc. Announces Third Quarter 2022 Results and Provides Business Update Host Conference Call Today, November 2, at 4:30pm ET Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatm
Read more →INMBINmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 26, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company
Read more →INMBINmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune Dr. Mark Lowdell, CSO, Presented Latest Data in First Plenary Session at The Innate Killer Summit Europe, London Tod
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune Dr. Mark Lowdell, CSO, Presented Latest Data in First Plenary Session at The Innate Killer Summit Europe, London Today BOCA RATON, Fla, Oct. 19, 2022 (GLOBE NEWSWIRE) -- IN
Read more →INMB▲ +6.3%on this news
INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference Boca Raton, FL
INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference FL, Sept. 07, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that h
Read more →INMBINmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update Company to Host Conference Call Today, August 3, at 4:30pm
Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update to Host Conference Call Today, August 3, at 4:30pm ET RATON, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on dev
Read more →INMBINmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: IN
Read more →INMBINmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease Alzheimer's Association International Conference ("AAIC") - Systems Biology of Alzheimer's Disease Panel on
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease Alzheimer's Association International Conference ("AAIC") - Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings, MD, ScD, and Krist
Read more →INMBUSPTO Issues Patent Covering Use of XPro for Treatment of CNS Diseases Boca Raton, Florida
USPTO Issues Patent Covering Use of XPro for Treatment of Boca Raton, Florida, June 22, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune syste
Read more →INMBINmune Bio, Inc. In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab based therapies, and promotes an immunological
pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab based therapies, and promotes an immunologically active TME. presented at noon today at the HER2 Targeted Therapy Summit in
Read more →INMBINmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer
In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to trastuzumab based therapies, and promotes an immunologically active TME. Data presented at noon today at the HER2 Targeted Therapy Su
Read more →INMBINmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595 in Alzheimer's Disease
INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595 in Alzheimer's Disease BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused
Read more →INMBINmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24 th Boca Raton, FL (
Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th Raton, FL (May 18, 2022) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disease, ann
Read more →INMBINmune Bio, Inc. Presents Data Demonstrating XPro Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation XPro Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improv
INmune Bio, Inc. Presents Data Demonstrating XPro Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation XPro Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improving Macrophage Phagocytosis (clearing) of Myelin Debris
Read more →INMBINmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update Company Dosed First Phase 2 Mild Alzheimer's Disease Patient with Xpro1595; Presented Data from Ongoing INKmune Studies Suggesting Increa
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Company Dosed First Phase 2 Mild Alzheimer's Disease Patient with Xpro1595; Presented Data from Ongoing INKmune Studies Suggesting Increased NK Cell Treatment Effective Against $66.7 Million in cash as of March
Read more →INMB▲ +6.8%on this news
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 28, 2022 - INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a
Read more →INMB▲ +16.2%on this newsshared move
INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference Boca Raton, FL (
Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference Raton, FL (April 25, 2022) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disease, announced today tha
Read more →INMB▲ +12.1%on this news
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer's disease INmune Bio Plans to Enroll 201 Patients in a 6-Month Study to Evaluate Cognitive Fun
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer's disease Bio Plans to Enroll 201 Patients in a 6-Month Study to Evaluate Cognitive Function in Patients with Mild Alzheimer's Disease Boca Raton, Flor
Read more →INMBINmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022 Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatme
Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022 Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastu
Read more →INMBINmune Bio, Inc. Highlights INKmune Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit INmune Bio, Inc. INKmune , unlike IL15 and other NK-activating cytokines, upregulates all mitochondrial survi
INmune Bio, Inc. Highlights INKmune Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit INKmune , unlike IL15 and other NK-activating cytokines, upregulates all mitochondrial survival proteins and more than 40 nutrient receptors on the NK cell to increas
Read more →INMBChallenges of NK Immunotherapy of Solid Tumours: Potentiation of intra - tumoral NK function Professor Mark Lowdell PhD, FRCPath, FRSB CSO INmune Bio Inc This presentation contains "forward - looking statements" Forward
Challenges of NK Immunotherapy of Solid Tumours: Potentiation of intra - tumoral NK function Professor Mark Lowdell PhD, FRCPath, FRSB CSO INmune Bio Inc This presentation contains "forward - looking statements" Forward - looking statements reflect our current view about future
Read more →INMBINmune Bio, Inc. Announces Company's CSO Dr. Mark Lowdell to Co-Host the "NK Cells in Solid Tumors" Workshop at Innate Killer Summit The Company also Plans on Sharing INKmune Patient Case Studies Boca Raton, Florida
Bio, Inc. Announces Company's CSO Dr. Mark Lowdell to Co-Host the "NK Cells in Solid Tumors" Workshop at Innate Killer Company also Plans on Sharing INKmune Patient Case Studies Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) ("INMB" or "the
Read more →INMBINmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD 2022 INmune Bio, Inc. International Conference on Alzheimer's and Parkinson's Diseases Provides New Insights into the Role of Neuroinflammation in AD and
Bio, Inc. Spotlights Key Findings in Presentations at AD/PD 2022 Conference on Alzheimer's and Parkinson's Diseases Provides New Insights into the Role of Neuroinflammation in AD and the Promise of Florida, March 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) ("IN
Read more →INMBINmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases
Conference Provides First Exposure of EU and UK AD Experts to INmune Bio’s Approach of Targeting Neuroinflammation and Glial Activation with XPro™ for Treatment of Alzheimer’s Disease Boca Raton, Florida, March 15, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “C
Read more →INMBINmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference Boca Raton, FL
Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that h
Read more →INMBINmune Bio, Inc. INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update Opens Phase 2 mild Alzheimer's trial and reports positive patient data from ongoing INKmuneTM trial in pa
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update Opens Phase 2 mild Alzheimer's trial and reports positive patient data from ongoing INKmuneTM trial in patient with high-risk myelodysplastic syndrome Cash of $74.8 million on De
Read more →INMB▼ -6.9%on this news· ran to -20% by day 3shared move
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update
Cash of $74.8 million on December 31, 2021 Company to host conference call today, March 3, at 4:30pm ET Boca Raton, Florida, March 03, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments
Read more →INMBINmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB
Read more →INMBINmune Bio, Inc. to Present at the BIO CEO & Investor Conference
INmune Bio, Inc. to Present at the BIO CEO & Investor Conference BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immu
Read more →INMBINmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer
Boca Raton, Florida, Jan. 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that the compan
Read more →INMB▼ -5.4%on this news· ran to -16% by day 3
INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting
Boca Raton, Florida, Jan. 04, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that management will part
Read more →INMBINmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium
Data suggests in triple negative breast cancer that MUC4 predicts survival and resistance to immunotherapy and that INB03 reverses resistance by decreasing immunosuppression in the TME Boca Raton, Florida, Dec. 09, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “
Read more →INMB▼ -8.2%on this news
INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial . Boca Raton, Florida
Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS Boca Raton, Florida, Dec. 01, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focu
Read more →INMB▼ -19.1%on this news
C O R P O R A T E P A R T I C I P A N T S David Moss, Co-Founder and Chief Financial Officer Raymond (R.J.) Tesi, MD, Co-Founder, President, CEO, Chief Medical Officer and Chairman Christopher (C.J.) Barnum, Director of
A T E P A R T I C I P A N T S David Moss, Co-Founder and Chief Financial Raymond (R.J.) Tesi, MD, Co-Founder, President, CEO, Chief Medical Officer and Chairman Christopher (C.J.) Barnum, Director Mark Lowdell, Co-Founder, Chief Scientific Officer & Chief Manufacturing Offi
Read more →INMB▼ -9.7%on this news· ran to -27% by day 1shared move
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Targeting Innate Immune Dysfunction INMB INVESTOR PRESENTATION November 2021 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward -
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Targeting Innate Immune Dysfunction INMB INVESTOR PRESENTATION November 2021 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking statements reflect our current view about future e
Read more →INMBINmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update Announces second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzhe
Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer's and cash equivalents of $84.5 million on September 30th to host con
Read more →INMBINmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting Boca Raton, Florida
Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting Raton, Florida, Oct. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on
Read more →INMBINmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida
Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 25, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (th
Read more →INMBINmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series Boca Raton, FL
INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series Boca Raton, FL, Sept. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing treatments that harness the p
Read more →INMB▼ -6.3%on this news
INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences
Inc. Announces Participation at Upcoming Investor Conferences BOCA RATON, Florida, Sept. 20, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune
Read more →INMB▲ +5.4%on this news· ran to -19% by day 3
H A R N E SS I N G T H E P O W E R O F T H E I NN A T E I MM U N E S Y S T E M Targeting Innate Immune Dysfunction I N M B INVESTOR PRESENTATION September 2021 F O R W A R D L OO K I N G S T A T E M E N T S This presenta
H A R N E SS I N G T H E P O W E R O F T H E I NN A T E I MM U N E S Y S T E M Targeting Innate Immune Dysfunction I N M B INVESTOR PRESENTATION September 2021 F O R W A R D L OO K I N G S T A T E M E N T S This presentation contains "forward - looking statements" Forward - look
Read more →INMBAlzheimer's Patients Treated with INmune Bio's XPro Show Reduction in CSF Phospho-Tau and Evidence of Remyelination XPro treatment shows statistically significant decrease in Phospho Tau 217 (pT271) and pT181, and an imp
Alzheimer's Patients Treated with INmune Bio's XPro Show Reduction in CSF Phospho-Tau and Evidence of Remyelination XPro treatment shows statistically significant decrease in Phospho Tau 217 (pT271) and pT181, and an improvement in an imaging biomarker of myelination. Company
Read more →INMBINmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming "Pseudokine", INKmune , Successfully Produced Memory-Like NK Cells First positive clinical confirmation of i
INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming "Pseudokine", INKmune , Successfully Produced Memory-Like NK Cells First positive clinical confirmation of in vivo NK response, mirroring Boca Raton, FL, Aug. 25, 2
Read more →INMB▲ +12.6%on this newsshared move
INKmune: An Interview With INmune Bio (INMB)'s Dr. Mark Lowdell TW Research (TW): Dr. Lowdell, thanks for speaking with us today. I know you've been involved with INKmune since the very beginning and was hoping that we c
INKmune: An Interview With INmune Bio (INMB)'s TW Research (TW): Dr. Lowdell, thanks for speaking with us today. I know you've been involved with INKmune since the very beginning and was hoping that we could start with the origins of the program. Where did the idea behind acti
Read more →INMBINmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual BOCA RATON, Florida, Aug. 10, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immun
Read more →INMB▲ +5.9%on this newsshared move
C O R P O R A T E P A R T I C I P A N T S David J. Moss , Chief Financial Officer Raymond J. Tesi, M.D. , Chief Executive Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Jonathan Aschoff, Ph.D., ROTH Capital
C O R P O R A T E P A R T I C I P A N T S David J. Moss, Chief Financial Officer Raymond J. Tesi, M.D., Chief Executive C O N F E R E N C E C A L L P A R T I C I P Jonathan Aschoff, Ph.D., ROTH Capital Mikhail Keyserman, BTIG Mayank Mamtani, B. Riley Securities Daniel Carl
Read more →INMB▲ +5.8%on this newsshared move
INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference
LA JOLLA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Raymond J. Tesi, MD, P
Read more →INMBINmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update
INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patie
Read more →INMBHARNESSING THE POWER OF THE INN A TE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB CORPORATE PRESENTATION August 2021 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking s
HARNESSING THE POWER OF THE INN A TE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB CORPORATE PRESENTATION August 2021 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking statements reflect our current
Read more →INMB▲ +9.1%on this news
INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4
Management to host conference call at 4:30 pm ET on that day BOCA RATON, Florida, July 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system
Read more →INMB▼ -23%on this newsshared move
INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer's Disease Clinical Trial and New Phase 1b AD Biomarker Data Phase 2 study of XPro TM will be a six-month, blinded, randomized, placebo-controlled trial in 1
INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer's Disease Clinical Trial and New Phase 1b AD Biomarker Data Phase 2 study of XProTM will be a six-month, blinded, randomized, placebo-controlled trial in 168 patients with mild Alzheimer's disease and biomarkers o
Read more →INMBINmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer's Association International Conference 2021 Boca Raton, FL
INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer's Association International Conference 2021 Raton, FL, July 19, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing
Read more →INMB▼ -13.9%on this newsshared move
INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING Boca Raton, FL.
INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING Boca Raton, FL., July 14, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune Bio"), a clinical-stage immunology company focused on developing treatments that harness a patient's
Read more →INMBINmune Bio, Inc. Announces First Patient Treated with NK cell priming " pseudokine" INKmune in High-Risk Myelodysplastic Syndrome (MDS) First-in-human open label Phase 1 study of INKmune will assess safety and tolerabili
INmune Bio, Inc. Announces First Patient Treated with NK cell priming "pseudokine" INKmune in High-Risk Myelodysplastic Syndrome (MDS) First-in-human open label Phase 1 study of INKmune will assess safety and tolerability and multiple measures of clinical activity and response
Read more →INMBINmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution Purchase of Xencor Option potentially eliminates approximately 2.1 million shares of INmune future common stock d
Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution of Xencor Option potentially eliminates approximately 2.1 million shares of INmune future common stock dilution upon execution. JOLLA, Calif, June 14, 2021 (GLOBE NEWSWIRE) -- IN
Read more →INMBINmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from
INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN LA JOLLA, Calif, June 02, 2021 (GLOBE NEWSWIRE) -- -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing treatmen
Read more →INMBINmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
LA JOLLA, Calif, May 24, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that RJ Tesi, MD, chief execu
Read more →INMBC O R P O R A T E P A R T I C I P A N T S David Moss, Chief Financial Officer, Treasurer & Secretary Raymond Tesi, MD, Co-Founder, President, Chief Executive Officer, Chief Medical Officer & Chairman C O N F E R E N C E
O R P O R A T E P A R T I C I P A N T S Moss, Chief Financial Officer, Treasurer & Secretary Tesi, MD, Co-Founder, President, Chief Executive Officer, Chief Medical Officer & Chairman O N F E R E N C E C A L L P A R T I C I P A N T S Aschoff, ROTH Capital Partners Mamtani, B
Read more →INMBINmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update Company to host conference call today, May 5, at 4:30pm
Inc. Announces First Quarter 2021 Results and Provides Business Update Company to host conference call today, LA JOLLA, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatmen
Read more →INMBINmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5 Management to host conference call at 4:30 pm ET on that day
Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5 Management to host conference call at 4:30 pm ET on that day JOLLA, Calif, April 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"), a c
Read more →INMBINmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference
LA JOLLA, Calif, April 26, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that Raymond J. Te
Read more →INMBProfessor Mark W Lowdell CSO 1 "Exploring the cellular interactions between NK cells, tumor cells and the TME" Tumor - derived Inhibitory signals Activating signals Tumor - derived Inhibitory signals Activating signals T
Professor Mark W Lowdell CSO 1 "Exploring the cellular interactions between NK cells, tumor cells and the TME" Tumor - derived Inhibitory signals Activating signals Tumor - derived Inhibitory signals Activating signals Tumor - derived Inhibitory signals Activating signals Activa
Read more →INMBINmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings Innate Killer Digital Summit 2021, which is being held March 23-25 Festival of Biologics USA: World Im
INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings Innate Killer Digital Summit 2021, which is being held March Festival of Biologics USA: World Immunotherapy Congress 2021, which is being held March 29-April
Read more →INMBINmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"), a clinical-stage immunology company focused on developing treatments that harne
Read more →INMBINmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update
LA JOLLA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for th
Read more →INMBINmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4 Management to host conference call and webcast at 4:30 pm ET on that day
Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4 to host conference call and webcast at 4:30 pm ET on that day JOLLA, Calif, Feb. 25, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Compan
Read more →INMBINmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer's Disease in Phase 1b Trial Interim data show CSF biomarkers of neurodegeneration and sy
Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer's Disease in Phase 1b Trial Interim data show CSF biomarkers of neurodegeneration and synaptic dysfunction as well as neuroimaging biomarkers improved a
Read more →INMBHARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB XPro1595 Alzheimer's KOL event
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB XPro1595 Alzheimer's KOL event Jan 21, 2021 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking statements reflect our
Read more →INMBINmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET Webinar to review expanded biomarker data from the company's Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patie
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET Webinar to review expanded biomarker data from the company's Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer's JOLLA, Calif, Jan. 12, 2021 (GLOBE
Read more →INMBHARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB CORPORATE PRESENTATION Nov 2020 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statem
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB CORPORATE PRESENTATION Nov 2020 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking statements reflect our current view
Read more →INMBINmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for Pulmonary Complications in COVID-19 Patients
LA JOLLA, Calif, Nov. 09, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the first patient has b
Read more →INMBC O R P O R A T E P A R T I C I P A N T S David Moss, Chief Financial Officer, Treasurer & Secretary RJ Tesi, Co-Founder, President, Chief Executive Officer, Chief Medical Officer & Chairman C O N F E R E N C E C A L L P
C O R P O R A T E P A R T I C I P A David Moss, Chief Financial Officer, Treasurer & Secretary RJ Tesi, Co-Founder, President, Chief Executive Officer, Chief Medical Officer & Chairman C O N F E R E N C E C A L L P A R T Jonathan Aschoff, ROTH Capital Julian Harrison, BTIG
Read more →INMBINmune Bio, Inc. Announces Third Quarter Results and Provides Business Update Company to host conference call today, November 5, at 4:30pm
Bio, Inc. Announces Third Quarter Results and Provides Business Update conference call today, November 5, at 4:30pm ET Nov. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that h
Read more →INMBINmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5
Management to host conference call at 4:30 pm ET on that day LA JOLLA, Calif, Oct. 29, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immun
Read more →INMBwww.roth.com Member: FINRA / SIPC 1 of 15 COVID - 19 Review October 2020 www.roth.com Member: FINRA / SIPC 2 of 15 Forward Looking Statements www.roth.com Member: FINRA / SIPC 3 of 15 Speaker: RJ Tesi MD CEO/CMO Dr . Tes
www.roth.com Member: FINRA / SIPC 1 of 15 COVID - 19 Review October 2020 www.roth.com Member: FINRA / SIPC 2 of 15 Forward Looking Statements www.roth.com Member: FINRA / SIPC 3 of 15 Speaker: RJ Tesi MD CEO/CMO Dr . Tesi has been President, Chief Executive Officer and acting C
Read more →INMBINmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer's Drug Discovery
INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer's Drug Discovery JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatme
Read more →INMBHARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM IN MB KOL Webinar on Treatment Resistant Depression
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM IN MB KOL Webinar on Treatment Resistant Depression Sept 29, 2020 Forward Looking Statements Major Depression Cancer Alzheimer's COVID19 PMID: 31806905 Common Fatal Disabling Major Depression 25 million adults in US Leading caus
Read more →INMBINmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29 LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treat
Read more →INMBINmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression 100 patient blinded, randomized, biomarker-directed
INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression 100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study t
Read more →INMBINmune Bio, Inc. to Participate in Oppenheimer's Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on
Bio, Inc. to Participate in Oppenheimer's Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September Calif., Sep. 14, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing treatmen
Read more →INMBINmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune Therapy
INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune Therapy LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing treatmen
Read more →INMBINmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 Patients Trial to evaluate the efficacy of Quellor to b
INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 Patients Trial to evaluate the efficacy of Quellor to blunt the cytokine storm and decrease the catastrophic co
Read more →INMBEuropean Patent Granted Covering INmune Bio's XPro1595
European Patent Granted Covering INmune Bio's XPro1595 JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fig
Read more →INMBC O R P O R A T E P A R T I C I P A N T S David J. Moss , Chief Financial Officer Raymond J. Tesi, M.D., Chief Executive Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Julian, BTIG Jonathan Aschoff, Roth Cap
C O R P O R A T E P A R David J. Moss, Chief Financial Officer Raymond J. Tesi, M.D., Chief Executive C O N F E R E N C E C A L L P A R T I C I P A N T S Jonathan Aschoff, Roth Capital Partners Naureen Quibria, Maxim Group Arthur He, H.C. Wainwright P R E S E N T A T I O
Read more →INMBINmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update The company will host an earnings call: Today, August 5 at 4:30
Inc. Announces Second Quarter 2020 Results and Provides Business Update The company will host an earnings call: Today, August 5 at LA JOLLA, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), an immunology company developing treatments
Read more →INMBINmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020
LA JOLLA, Calif, Aug. 03, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that management wil
Read more →INMBINmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results
INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results LA JOLLA, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"), a clinical-stage immunology company focused on developing treatments that
Read more →INMBHARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB CORPORATE PRESENTATION Aug 2020 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statem
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB CORPORATE PRESENTATION Aug 2020 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking statements reflect our current view
Read more →INMBINmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm
INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm LA JOLLA, Calif, July 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate im
Read more →INMBCorrection: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Over-Allotment Option
Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Over-Allotment Option LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, July 20th by
Read more →INMBINmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Over-Allotment Option
INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Over-Allotment Option LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"), a clinical-stage
Read more →INMBINmune Bio, Inc. Prices Public Offering of Common Stock
Prices Public Offering of Common Stock JOLLA, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight dise
Read more →INMBINmune Bio, Inc. Announces Proposed Public Offering of Common Stock
LA JOLLA, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it has co
Read more →INMBHARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB XPro1595 KOL Webinar on Alzheimer's
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB XPro1595 KOL Webinar on Alzheimer's July 14, 2020, 8AM EST FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking statemen
Read more →INMBINmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease
LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today reported clinical data demonstrating tha
Read more →INMBINmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer's Disease Prior to Start of AAIC 2020 Data Focused on Biomarkers of Neuroinflammation will be Topic of Key Opi
Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer's Disease Prior to Data Focused on Biomarkers of Neuroinflammation will be Topic of Key Opinion Leaders Call Set for July 14 at 8:00 AM Eastern Time LA JOLLA, Calif., July 09
Read more →INMBINmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS Study will be the first-in man trial for INKmune - a novel therapy to prime the patient's own
Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS Study will be the first-in man trial for INKmune - a novel therapy to prime the patient's own NK cells to attack their cancer LA JOLLA, Calif., June 11, 2020 (GLO
Read more →INMBKillers at the Crossroad - A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio, Inc. Review highlights the history, progress and potential of cells of
Killers at the Crossroad - A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio, Inc. highlights the history, progress and potential of cells of the innate immune system that can be harnessed for treatment of c
Read more →INMBHARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB CORPORATE PRESENTATION May 2020 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statem
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB CORPORATE PRESENTATION May 2020 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking statements reflect our current view
Read more →INMBINmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update The company will host an earnings call: Today, May 14 at 4:30
INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update The company will host an earnings call: Today, May 14 at 4:30 PM ET LA JOLLA, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), an immunology company d
Read more →INMBINmune Bio Inc’s INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response in Pre-clinical Models of Trastuzumab-Resistant HER2+ Breast Cancer
Study provides rational for use of INB03 and Lapatinib in INmune Bio’s upcoming Phase II trial and may offer new therapy for women with CNS metastasis from HER2+ breast cancer because both drugs cross blood brain barrier LA JOLLA, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- INmune
Read more →INMBINmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call
Bio, Inc. to Host First Quarter 2020 Earnings Conference Call JOLLA, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease,
Read more →INMBHARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating the Innate Immune Response Against Disease IN MB Treating COVID - 19 a s a n Inflammatory Disease FORWARD LOOKING STATEMENTS This presentation contains "forward
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating the Innate Immune Response Against Disease IN MB Treating COVID - 19 a s a n Inflammatory Disease FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking statements reflect
Read more →INMBINmune Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Group's Infectious Disease Virtual Conference on
Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Group's Infectious Disease Virtual Conference on May 5, 2020 Calif., April 28, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patie
Read more →INMBFrontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF's Impact on Breast Cancer Neutralization of Soluble TNF may decrease progression of breast cancer and lessen resistance to breast cancer immunoth
Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF's Impact on Breast Cancer Neutralization of Soluble TNF may decrease progression of breast cancer and lessen resistance to breast cancer immunotherapy LA JOLLA, Calif., April 23, 2020 (GLOBE NEWSWIRE)
Read more →INMBINmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells GlobeNewswire
INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells LA JOLLA, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that
Read more →INMBINmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company's TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 Conference call
INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company's TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 Conference call at 4:15 PM ET with management to discuss the science an
Read more →INMBINmune Bio DN-TNF Clinical Trial, Complications of Cytokine Storm Caused by COVID-19
DN-TNF Clinical Trial, Complications of Cytokine Storm Caused by COVID-19 and Chief Medical Officer John Aschoff - Roth Capital Michael Carmia - BTIG Jason McCarthy - Maxim Group R.K. - H.C. Wainwright Carl Byrnes - Northland Securities Greetings, and welcome to INmune Bi
Read more →INMBHARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB INVESTOR PRESENTATION 2Q 20 V1 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking stateme
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB INVESTOR PRESENTATION 2Q 20 V1 FORWARD LOOKING STATEMENTS This presentation contains "forward - looking statements" Forward - looking statements reflect our current view
Read more →INMBINmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer's Disease and NASH Company will host an investor conference call today at 11:00
INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer's Disease and NASH Company will host an investor conference call today at LA JOLLA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:
Read more →INMBINmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17
INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17 LA JOLLA, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunology company developing treatments that harness the patient's innate immune system to fight disease, today announced tha
Read more →INMBINmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results
INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results LA JOLLA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient's innate immune system to tre
Read more →INMBINmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS Grant will fund proof-of-concept studies for XPro1595 therapy
Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS will fund proof-of-concept studies for XPro1595 therapy JOLLA, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunolog
Read more →INMBINmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals Dr. Mal Tansey's peer-reviewed data from INmune Bio's lead compound XPro15
INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals Dr. Mal Tansey's peer-reviewed data from INmune Bio's lead compound XPro1595 published in Alzheimer's Research & Therapy LA JOLLA,
Read more →INMBINmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials
Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer LA JOLLA, Calif. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunology company developing therapies that reprogram the patient’s innate immune system to treat diseases, today announce
Read more →INMBBio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing
Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing II program to focus on women with trastuzumab resistant HER2+ breast cancer JOLLA, Calif. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc., a
Read more →INMBINmune Bio, Inc. Announces First Alzheimer's Disease Patient Dosed in XPro1595 Study Neuroinflammation targeted in XPro1595 Phase Ib clinical trial
INmune Bio, Inc. Announces First Alzheimer's Disease Patient Dosed in XPro1595 Study targeted in XPro1595 Phase Ib clinical trial Dec. 02, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient's innate i
Read more →INMBINmune Bio Inc. to Discuss Potential New Alzheimer's Disease Treatments in CTAD Pre-Conference Webinar INmune Bio's CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Al
Bio Inc. to Discuss Potential New Alzheimer's Disease Treatments in CTAD Pre-Conference Webinar Bio's CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer's JOLLA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- -- INmune Bio
Read more →INMBINmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen
INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen LA JOLLA, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient's innate immune
Read more →INMBINmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update
INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), an immunology company developing treatments that harness the patient's innate imm
Read more →INMBINmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting
Dr. Malú Tansey’s new data highlighted at today’s press conference LA JOLLA, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today t
Read more →INMBINmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience's Annual Meeting Data on Neuroinflammation and Alzheimer's Disease to be Presented by Dr. Mal Tansey;
Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience's Annual on Neuroinflammation and Alzheimer's Disease to be Presented by Dr. Mal Tansey; Presentation Selected for Meeting's JOLLA, Calif., Oct. 16, 2019 (GLOBE NEWSWI
Read more →INMBINmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October
INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October LA JOLLA, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the pa
Read more →INMBCEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq's MarketSite and Announces Presentation at World Immunotherapy Congress La Jolla, CA.
CEO of INmune Bio Inc. Discusses Accomplishments at Nasdaq's MarketSite and Announces Presentation at World Immunotherapy Congress Jolla, CA., Sept. 24, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harne
Read more →INMBINmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer's Disease at 2019 Alzheimer's Association International Conference (AAIC) Satellite Symposium
INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer's Disease at 2019 Alzheimer's Association International Conference (AAIC) LA JOLLA, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatm
Read more →INMBINmune Bio Invited to Speak on Company's Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress La Jolla, CA.
INmune Bio Invited to Speak on Company's Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress La Jolla, CA., Sept. 16, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company
Read more →INMBINMUNE BIO INC. ANNOUNCES USPTO ALLOWANCE OF KEY PATENT COVERING ITS DN-TNF PLATFORM TECHNOLOGY FOR TREATING CANCER La Jolla, CA
INMUNE BIO INC. ANNOUNCES USPTO ALLOWANCE OF KEY PATENT COVERING ITS DN-TNF PLATFORM TECHNOLOGY FOR La Jolla, CA September 12, 2019 INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that reprogram the patient's innate immune
Read more →INMBINMB non - confidential3Q19.v5
INMB non - confidential3Q19.v5 This presentation contains "forward - looking statements" Forward - looking statements reflect our current view about future events . When used in this presentation, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan
Read more →INMBINmune Bio to Present at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September 10th at 2:10 p.m. ET
LA JOLLA, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to announce that R.J. Tesi, M.D., the Company’s Co-founder and
Read more →INMBINmune Bio Inc. to Introduce NeuLiv Program for Treatment of NASH at H.C. Wainwright 21 st Annual Global Investment Conference NeuLiv is the Third Drug Development Program From Company's DN-TNF Platform Presentation is S
INmune Bio Inc. to Introduce NeuLiv Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference NeuLiv is the Third Drug Development Program From Company's DN-TNF Platform Presentation is Scheduled for 2.10 LA JOLLA, Calif., Sept. 4, 2019 (GLO
Read more →INMBINmune Bio Inc.
Company Contact: INmune Bio Inc. (NASDAQ: INMB) David Moss, Chief Financial Officer PH: (858) 964 - 3720 Dmoss@INmuneBio.com Investor Contact: KCSA Strategic Communications Valter Pinto / Daniela Guerrero PH: (212) 896 - 1254 / (347) 487 - 6187 INmune@KCSA.com INmune Bio Inc . (N
Read more →INMBINMB non - confidential3Q19.v2
INMB non - confidential3Q19.v2 This presentation contains "forward - looking statements" Forward - looking statements reflect our current view about future events . When used in this presentation, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan
Read more →INMBINmune Bio Reports Second Quarter 2019 Financial Results and Provides Shareholder Update La Jolla, CA
Reports Second Quarter 2019 Financial Results and Provides Shareholder Update La Jolla, CA - August 12, 2019 - INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), an immunology company focused on developing treatments that harness the patient's innate immune system to fight disea
Read more →INMBINmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member
LA JOLLA, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to announce that Edgardo (Ed) Baracchini, Ph.D., has joined the
Read more →INMBINmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member La Jolla, CA
INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member La Jolla, CA - August 6, 2019 - INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced
Read more →INMBINmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer La Jolla, CA
INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer La Jolla, CA - August 5, 2019 - INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, repo
Read more →INMBINmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute's 7th Annual Immuno-Oncology Summit La Jolla, CA.
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute's 7th Annual Immuno-Oncology Summit La Jolla, CA. - Aug. 1, 2019 - INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient's innate immune sy
Read more →INMBINmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Science & Technology 2019 La Jolla, CA
INmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Science & Technology 2019 La Jolla, CA - July 25, 2019 - INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient's innate immu
Read more →INMBINmune Bio Co-Founder and CEO Presents at Maxim Group's Conference on Alzheimer's Disease La Jolla, CA
INmune Bio Co-Founder and CEO Presents at Maxim Group's Conference on Alzheimer's Disease La Jolla, CA - July 3, 2019 - INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, annou
Read more →INMBINmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE La Jolla, CA
INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE La Jolla, CA - June 27, 2019 - INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments that harness the patient's innate immune system to fight disease,
Read more →INMBINmune Bio Inc. Featured in Exclusive NetworkNewsWire Broadcast
INmune Bio Inc. Featured in Exclusive NetworkNewsWire Broadcast NEW YORK, June 11, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio - INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient's innate immune system to fight dise
Read more →INMBINmune Bio to present Alzheimer's Drug Candidate XPro1595 at The TNF Conference La Jolla, CA
INmune Bio to present Alzheimer's Drug Candidate XPro1595 at The TNF Conference La Jolla, CA - June 4, 2019 - INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced
Read more →INMBINmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th
INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th May 28, 2019 09:03 ET | Source: INmune BIO, Inc. LA JOLLA, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness th
Read more →INMBINmune Bio Announces Common Stock Purchase Agreement for up to $20.0 Million with Lincoln Park Capital
LA JOLLA, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced a common stock purchase agreement with Lincoln Park Capital
Read more →INMBINmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update GlobeNewswire
INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update GlobeNewswire May 15, 2019 LA JOLLA, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), an immunology company focused on developing treatments that harness the patient'
Read more →INMBINmune Bio Closes Private Placement of Approximately $4.1 Million of Common Stock, Led by Insiders and Existing Shareholders GlobeNewswire
INmune Bio Closes Private Placement of Approximately $4.1 Million of Common Stock, Led by Insiders and Existing Shareholders GlobeNewswire May 7, 2019 LA JOLLA, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing
Read more →INMBINmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit
INmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit LA JOLLA, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient's innate immune system to fight disea
Read more →INMBINmune Bio Co-Founder and CEO to Speak at Cambridge Healthtech Institute’s 10th Annual Inflammation Inhibitors Conference
LA JOLLA, Calif., April 09, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., the company’s co-founder and CEO, wil
Read more →INMBINmune Bio Announces Poster Presentation with New Data Regarding Neurodegenerative Disease Drug Candidate, XPro1595, at The European Conference on Neuroinflammation
INmune Bio Announces Poster Presentation with New Data Regarding Neurodegenerative Disease Drug Candidate, XPro1595, at The European Conference on Neuroinflammation LA JOLLA, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focu
Read more →INMBINmune Bio to Ring the NASDAQ Closing Bell on Tuesday, April 9, 2019
LA JOLLA, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its Chief Executive Officer, Raymond J. T
Read more →INMBINmune Bio Co-Founder and CEO Presented at Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit Europe 2019
LA JOLLA, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that R.J. Tesi, M.D., the company’s co-founder and CEO, p
Read more →INMBCLINICAL TRIALS XPro1595 XPro1595 Development Philosophy Alzheimer's disease was first described over 100 years ago. Today, we recognize that it is a complicated disease that may have more than one cause. Given the heter
CLINICAL TRIALS XPro1595 XPro1595 Development Philosophy Alzheimer's disease was first described over 100 years ago. Today, we recognize that it is a complicated disease that may have more than one cause. Given the heterogeneity of Alzheimer's disease, a single therapy is unlik
Read more →INMBINmune Bio Co-Founders to Present at World Immunotherapy Congress during the Festival of Biologics San Diego Presentations to address the role of the innate immune system in treating cancer
INmune Bio Co-Founders to Present at World Immunotherapy Congress during the Festival of Biologics Presentations to address the role of the innate immune system in treating cancer LA JOLLA, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunolog
Read more →INMBINmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer's Disease The Alzheimer's Association awarded INmune Bio the Part the Cloud to RESCUE grant to target neuroinflammation
INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer's Disease The Alzheimer's Association awarded INmune Bio the Part the Cloud to RESCUE grant to target neuroinflammation in Alzheimer's Disease LA JOLLA, Calif., Feb. 11, 2019 (G
Read more →INMBINmune Bio to Present at BIO CEO & Investor Conference
LA JOLLA, CA, Feb. 06, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (Nasdaq: INMB) (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease, today announces that R.J. Tesi, M.D., President
Read more →INMBINmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol "INMB"
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol "INMB" LA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. ("INmune" or the "Company"), an immunotherapy company focused on developing thera
Read more →INMBINmune Bio, Inc. Announces Pricing of Initial Public Offering
INmune Bio, Inc. Announces Pricing of Initial Public Offering LA JOLLA, CA, January 15, 2019 (GLOBE NEWSWIRE)- INmune Bio, Inc. ("INmune" or the "Company"), an immunotherapy company focused on developing therapies that harness the patient's innate immune system to fight disease,
Read more →INMBINmune Bio Granted Phase I Clinical Trial Authorization of Lead Product INKmune™ in Refractory and Recurrent Ovarian Cancer Patients
LA JOLLA, California, Dec. 19, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, announced today that it has been granted Clinical Trial Authorization (CTA) by the United Kingdom (UK) r
Read more →INMBINmune Bio Announces Publication of Myeloid-Derived Suppressor Cells (MDSC) Report in the Cell’s Trends in Pharmacological Sciences Journal
Manuscript highlights the vital role of MDSC in the tumor microenvironment (TME) LA JOLLA, Calif.,, Dec. 07, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, announced today that Cel
Read more →INMBINmune Nominated for Buzz of Bio Award at 2019 CEO & Investor Conference
-Voting begins today: Click here to cast your vote- LA JOLLA, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease , today announced that the Company
Read more →INMBINmune Bio Co-Founder and CSO Named Regional VP to the Board of International Society of Cell and Gene Therapy (ISCT)
LA JOLLA, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- INmune Bio, Inc., an immunotherapy company developing treatments to reprogram the patient’s innate immune system, today announces that its co-founder and chief scientific officer, Mark Lowdell, Ph.D., has been
Read more →INMBINmune Bio Named Finalist for Lifestars’ U.S. Private Company of the Year Award
Recognized for big strides in cancer immunotherapy treatments LA JOLLA, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, announced today that it h
Read more →INMBINmune Bio Co-Founder and Chief Scientific Officer Mark Lowdell, Ph.D., Chairing Sessions at International Society of Cell and Gene Therapy (ISCT) European Regional Meeting
LA JOLLA, Calif. , Sept. 12, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – INmune Bio, Inc., an immunotherapy company developing treatments to reprogram the patient’s innate immune system, today announced that Co-Founder and Chief Scientific Officer Mark Lowdell, Ph.D., is co-hostin
Read more →INMBINmune Bio to Present at Two Prestigious Cambridge Healthtech Institute Events
LA JOLLA, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, today announces that its co-founder and CEO, Raymond J. Tesi, M.D., will participate in a
Read more →INMBINmune Bio CEO Dr. Raymond J. Tesi to Present at 14th Annual Biomarkers & Immuno-Oncology World Congress
Session will focus on emerging targets and therapeutic strategies to address resistance in immunotherapy LA JOLLA, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing treatments to reprogram the patient’s innate immune system to combat
Read more →INMBINmune Bio Initiates Phase I Clinical Trial of INB03
LA JOLLA, Calif., May 23, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat cancer, today announced that it has initiated a Phase 1 clinical trial of its drug candi
Read more →INMBINmune Bio Co-Founder and Chief Scientific Officer Mark Lowdell, PhD, Delivers Keynote at CTERP International Conference
LA JOLLA, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat cancer, announces that co-founder and Chief Scientific Officer Mark Lowdell, PhD, delivered the keynote
Read more →INMBINmune Bio’s Professor Mark Lowdell to Participate as Expert Speaker at the Third Annual Innate Killer Summit 2018
LA JOLLA, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system, announces that Mark Lowdell, Ph.D., professor of Cell and Tissue Therapy at Uni
Read more →INMBINmune Bio Appoints Scott Juda to Board of Directors
LA JOLLA, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system to attack their cancer, announces the appointment of Scott Juda, J.D., to its b
Read more →INMBINmune Bio to Present at Upcoming Conferences
LA JOLLA, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system to attack their cancer, today announced that company CEO and President RJ Tesi, M
Read more →INMBINmune Bio presenting at NobleCon14 on January 29th
LA JOLLA, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- via Network NewsWire – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system to attack their cancer, today announced that company CEO and President RJ Te
Read more →INMBINmune Bio Appoints Edgardo Baracchini to its Board of Directors, Gains Additional Licensing and Business Development Expertise
LA JOLLA, CA--(Marketwired - Oct 16, 2017) - INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, today announces the appointment of Edgardo "Ed" Baracchini, PhD. to its board of d
Read more →INMBINmune Bio to Present at the BIO Investor 2017 Healthcare Conference
LA JOLLA, CA--(Marketwired - Oct 11, 2017) - INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, today announces that company president and CEO RJ Tesi MD will present at the BIO
Read more →INMBINmune Bio Licenses INB03, a First-in Class Innate Immune System Check-Point Inhibitor that Targets Myeloid Derived Suppressor Cells in Cancer
LA JOLLA, CA--(Marketwired - Oct 10, 2017) - INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, announces that it has licensed INB03, a novel innate immune system check-point inh
Read more →INMBINmune Bio Licenses Technology to Deplete Myeloid Derived Suppressor Cells of the Innate Immune System in Patients with Cancer
LA JOLLA, CA--(Marketwired - Oct 9, 2017) - INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, announced they obtained a license to intellectual property developed by Dr. Nikola
Read more →INMBINmune Bio Adds Clinical Development and Product Development Expertise with the Appointment of Tim Schroeder to its Board of Directors
LA JOLLA, CA--(Marketwired - Sep 26, 2017) - INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, today announces the appointment of Timothy J. Schroeder to its board of directors.
Read more →Competitive Position
How INMB ranks across every disease it competes inCompetitive Position is a premium feature
See how INMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial